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Abstract
Esophagectomy remains an integral part of cure for patients with esophageal cancer.
The operation can be a source of significant morbidity and mortality, which highlights
the importance of preoperative risk assessment and careful patient selection.
Sarcopenia, defined as loss of muscle and function, and frailty are two measures of
decreased physiologic reserve that have been associated with poor outcome in cancer
patients. The first objective of this thesis was to summarize the existing literature on the
available tools used to quantify frailty and sarcopenia. The second was to perform the
first study using the National Surgical Quality Improvement Program (NSQIP) database
to investigate the association between the 5-factor modified frailty index (mFI-5) and
adverse outcomes in esophagectomy patients. The final objective was to measure
sarcopenia and frailty in the same local esophagectomy patient cohort to investigate the
association between these metrics of physiologic reserve and severe postoperative
complications requiring intensive care. NSQIP data for esophagectomy patients from
2016-2018 were obtained and local patient data was collected from 2010-2016. Frailty
was quantified using mFI-5 and sarcopenia status was attained by normalizing skeletal
muscle area on preoperative computed tomography scans by sex and height. Based on
the NSQIP database, mFI-5 showed associations with post-esophagectomy 30-day
morbidity (i.e., Clavien-Dindo grade IV complications) but not mortality. In the local
patient cohort, neither sarcopenia nor mFI-5 demonstrated significant associations with
postoperative outcomes. In conclusion, sarcopenia and frailty are markers of
physiologic vulnerability but may not correspond with statistically and clinically
significant outcomes for esophagectomy patients.

Keywords
Esophageal cancer, esophagectomy, frailty, sarcopenia, NSQIP, mFI, outcomes,
Clavien Dindo, morbidity, mortality
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Summary for Lay Audience
The definitive surgical treatment for esophageal cancer is an esophagectomy – a
complex and physiologically taxing operation in patients already ill patients. The risks of
death and severe complications associated with this surgery is high. For this reason,
finding a way to understand which patients would do poorly afterwards is important for
making decisions about treatment. Sarcopenia is a condition defined by loss of muscle
mass and function. Frailty is the overall decline in the body’s ability to respond to stress.
Both factors have both been linked to poor outcomes in cancer patients. In our
research, we first aimed to summarize the ways sarcopenia and frailty are measured.
Second, we investigated whether the 5-factor modified frailty index (mFI-5) – a simple
and widely used tool to quantify frailty – was associated with poor outcomes in
esophagectomy patients that were captured in the National Surgical Quality
Improvement Program (NSQIP) database between 2016-2018. Ours was the first study
to apply mFI-5 to these patients. Finally, we took our local population of esophagectomy
patients and measured both frailty (using the mFI-5) and sarcopenia (using preoperative
computed tomography (CT) scans) to see if either metric was more associated with
outcomes severe enough to warrant admission to the intensive care unit (ICU). Based
on the NSQIP database study, we found that the mFI-5 was associated with severe
complications but not death within 30 days of surgery. In our local cohort, we did not
find any meaningful indications that sarcopenia or mFI-5 were associated with
admission to the ICU. In conclusion, both sarcopenia and frailty are objective measures
of physiologic vulnerability, but these two metrics alone may not be enough to tell us
whether a patient undergoing an esophagectomy will have a poor outcome that is
clinically meaningful.
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Chapter 1 – Introduction
1.1 Epidemiology and Etiology of Esophageal cancer
Esophageal cancer is one of the most lethal gastrointestinal tract malignancies and a
major cause of cancer mortality worldwide. The incidence of esophageal cancer has
increased sharply over the past few decades. According to the GLOBOCAN 2020
estimates, esophageal malignancies rank 7th in terms of incidence, with 604 100 new
cases diagnosed in 20201. It accounted for 5.5%, or 1 in 20, of all cancer deaths,
making esophageal cancer the 6th leading cause of death from a malignant neoplasm in
the world1.

The highest rates of esophageal cancer are found in Southern African countries, as well
as the Asian “cancer belt” that extends from China to eastern Turkey and northeastern
Iran1–3. Cancers arising from the esophagus are relatively uncommon in North America,
where the rate of new cases per year is 4.3 per 100,000, compared to 18 per 100 000 in
Eastern Asia4. Its incidence, however, has steadily risen over the past 25 years5.

The risk of esophageal carcinoma increases with age, with a mean age at diagnosis of
66 years. Overall, esophageal cancer is four times more common and slightly more
lethal in men than in women. Survival varies widely depending on cancer site,
histopathology, treatment modality, and stage of disease. According to the Surveillance,
Epidemiology and End Results (SEER) registry estimates from 2010-2016, the overall
5-year survival for esophageal cancer is just under 20%. This poor survival is largely
because esophageal cancer is often diagnosed at a late stage. If the disease is
confined to local or regional tissues, survival ranges from 25-47%. Small tumors are
often asymptomatic and detected by chance. Once symptoms are present (e.g.,
dysphagia, weight loss), esophageal cancers have usually become locally invasive and
may have metastasized to lymph nodes or other organs. Most patients have advanced
disease with distant metastasis at the time of diagnosis (39%). For the these patients,
the 5-year survival is only 5% 6, 7.
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The two most common histological types of esophageal cancer are squamous cell
carcinomas (SCC) and adenocarcinomas. Other rare malignancies of the esophagus,
including sarcomas and small cell carcinomas, represent less than 2% of all esophageal
cancers. Even rarer are cases of melanomas, leiomyosarcomas, carcinoids, and
lymphomas8. SCC arises from the stratified squamous epithelial lining and is the
predominant histologic type of esophageal cancer worldwide4. Transition models
describe squamous epithelium undergoing inflammatory changes that progress to
dysplasia and in situ malignant change, resulting in SCC9. It is relatively evenly
distributed between the middle and lower third of the esophagus, in contrast to
adenocarcinomas, which is predominantly found in the distal esophagus.
Adenocarcinoma arises from the columnar-lined metaplastic epithelium, commonly
known as Barrett’s esophagus, which replaces the squamous epithelium and may
progress to dysplasia10. Gastroesophageal reflux disease (GERD) can damage the
lining of esophagus causing Barrett’ s esophagus. Although Barrett’s only develops in
approximately 5 to 8% of patients with GERD, patients with Barrett’s esophagus have a
50 to 100 times increase in their risk of developing cancer compared to the general
population11.

1.2 Treatment of esophageal cancer
Treatment of esophageal cancer depends on the stage of cancer at presentation (Table
1). In medically fit patients in the absence of systemic metastasis (Stage I – III disease),
surgery is a vital component of curative therapy. An esophagectomy – the surgical
resection of the esophagus - is a long, complex procedure that has historically been
associated with significant perioperative morbidity and mortality12,13.
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Table 1 – Staging of Esophageal cancer14,15
Stage

Description

Stage 0

Early-stage; carcinoma in situ, a precancerous change

Stage 1

Early-stage; the tumour is small and has not grown outside of the organ
it started in

Stage 2 - 3

Locally advanced; the tumour is larger or has grown outside of the
organ it started into nearby tissue with involvement of lymph nodes

Stage 4

Metastatic; the cancer has spread through the blood or lymphatic
system to a distant site in the body

The ﬁrst successful esophagectomy for intrathoracic esophageal cancer was reported
almost 100 years ago by Torek in 191316. It was not until 20 years later that resection
followed by immediate reconstruction was described in a series by Oshawa of Japan 17.
The early experience with esophagectomy from the 1950s to 1970s was plagued with
high rates of perioperative mortality, reaching up to 30%18. As the disease, medical
science, and technology evolved, so have the surgical techniques, which now include at
least seven different surgical procedures that can be labeled “esophagectomy.”
Considerable advances in the understanding, treatment, and management of
esophageal cancer in the second half of the 20th century greatly improved operative
mortality. Studies from high-volume centers in the last 20 years have reported mortality
less than 5% 19,20. Despite these advances, morbidity after esophagectomy remains
substantial, with rates over 60% in some series 21–23.

Over the past few decades, treatment modalities have evolved into a complex array of
therapeutic choices involving some combination of chemotherapy, radiation therapy,
and surgical resection. For early-stage minimally invasive esophageal cancer (Table 1),
resection alone offers high rates of cure. In a comparison between endoscopic and
surgical resection of Barrett's esophagus – a precancerous change to the esophageal
epithelium – surgery was associated with higher risk of morbidity and procedure-related
mortality but comparable overall survival 24,25. It should be noted, however, that the
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recurrence rate is higher in patients treated with endoscopic resection, and thorough
endoscopic surveillance is necessary24,25.

Although preoperative chemoradiation remains a subject of debate for early-stage
tumors, the implementation of multimodal strategies for locally advanced (Table 1)
esophageal cancer has improved both recurrence rates as well as patient survival 26–28.
Neoadjuvant chemoradiotherapy followed by surgery is a strategic option in the
treatment of potentially resectable advanced esophageal cancer. The benefit of
neoadjuvant chemoradiation was historically controversial because of contradictory
results in the early randomized studies29–32. More recent randomized studies and metaanalyses have provided strong evidence for survival benefit to support neoadjuvant
therapy followed by surgery compared to surgery alone for patients with stages III and
IVA esophageal cancer 27,33,34. It is currently common practice to treat locally advanced
disease with tri-modality therapy (concurrent chemotherapy and radiation followed by
surgery) after the encouraging results of the Chemoradiotherapy for Oesophageal
Cancer Followed by Surgery Study (CROSS) were published in 201227. This study
reported a remarkable increase in survival in patients with locally advanced esophageal
cancer undergoing esophagectomy after chemoradiotherapy with similar rates of
postoperative complications. It should be noted, however, that the CROSS trial only
recruited patients who had a World Health Organization (WHO) performance status
score of 2 or lower (on a scale of 0 to 5, with 0 indicating fully active, 1 unable to carry
out heavy physical work, and 2 up and about more than half the day but unable to work)
and had lost 10% or less of body weight.

The emphasis on performance status in patient selection and implicit recognition of this
dimension on treatment outcome can also be seen in recent studies for adjuvant
therapy. In the 2021 CheckMate 577 trial – a global, randomized, double-blind, placebocontrolled phase III trial of patients who received neoadjuvant chemoradiotherapy and
resected (R0) stage II or III esophageal cancer but was found to still have residual
pathological disease - receiving the checkpoint inhibitor, nivolumab, increased median
disease-free-survival and decreased risk of disease recurrence and death for both
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adenocarcinomas and squamous cell carcinomas35. It is important to note that the
patient selection for this trial only included those with an Eastern Cooperative Oncology
Group (ECOG) performance score of 0 or 1, meaning they were fully active or only
restricted in physically strenuous activity. The ECOG Performance Status is commonly
used as a prognostic tool or selection criterion in patients with active cancer going under
treatment36,37. It is one of many tools used to quantify functional status as related to
physiologic reserve and frailty, which are patient factors that may explain differences in
disease and treatment outcomes. This inclusion criterion of only patients with good
performance status was similarly seen in the landmark 2006 MAGIC trial, which found
that peri-operative chemotherapy improves the five-year progression-free and overall
survival in patients with stage II and III adenocarcinoma of the distal esophagus and
stomach26. By excluding patients with poor performance status, it is clear that this
parameter is a significant consideration in the assessment of a patient’s ability to
tolerate a proposed treatment. We anticipate seeing increasing numbers of patients with
poor performance status, and as such, the impact that has on the recovery path after
intervention must be further elucidated.

1.3 Post-esophagectomy Complications
The overall incidence of post-esophagectomy complications ranges from 20-68%, which
includes both complications specific to the procedure (e.g., anastomotic leaks,
chylothorax) and systemic complications (e.g., pneumonia, myocardial infarction,
prolonged ventilator requirement) 21,35,36. Anastomotic leaks, one of the most serious
postoperative complications, happen to one in ten patients; however, some studies
report leaks rates as high as 26% 38–43. Anastomotic leak is associated with a significant
increases in mortality44,45. Cardiorespiratory complications are also relatively common
after esophagectomy, including pneumonia, myocardial infarction, and transient
arrhythmia. Many of these complications necessitate intensive care unit (ICU)-level
care while they are being managed.
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Preoperative factors that are known to increase the risk of complications following
esophagectomy include age, pulmonary compromise (e.g., chronic obstructive
pulmonary disease), malnutrition, renal or hepatic dysfunction, and emergency
surgery37. Comorbid illnesses, such as cardiovascular disease, diabetes, chronic
obstructive pulmonary disease (COPD), and hypertension, increase the risk of
postoperative rates of anastomotic leaks, cardiorespiratory complications, reoperation,
and death following an esophagectomy 46,47.

1.4 Measurements of physiologic reserve
A major challenge for patients with esophageal cancer is the impact of the disease and
treatment on physiological reserve. These patients are often malnourished at diagnosis
due to local tumor effects causing symptoms such as dysphagia, vomiting, inadequate
nutritional intake, fatigue, weight and muscle loss48, 49, which results in a suboptimal
state for treatment 50, 51. Compounding disease-related declines in physiologic reserve
are the health consequences that come with aging. According to the United States
census bureau, 20% of Americans will be older than 65 years in 2030 and half of them
will need an operation - equating to about 36 million older surgical patients52. The
incidence of esophageal cancer increases with age, and the process of aging is
associated with an increasing prevalence of frailty, comorbidities, and a decline of
functional reserve. This can contribute to a higher risk of complication, particularly in
malnourished surgical patients.
Post-operative complications are multifactorial and can impact not only the patient’s
quality of life, but also delay adjuvant therapy and adversely affect survival. It is
therefore crucial to identify those patients with poor prognostic indicators. In recent
years, there has been a growing interest in pre-surgical optimization in an effort to
improve physiologic reserve and decrease postoperative morbidity. This has led to
investigations into specific patient factors, such as frailty and sarcopenia, which might
be used in quantifiable preoperative risk stratification. While evidence suggest there is a
link between lower physiologic reserve and poor post-operative outcomes, a clear and
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actionable method of identifying patients at higher risk who are candidates for
esophagectomy is still known.

1.4.1 Frailty
Frailty is a multidimensional state of increased vulnerability. In medicine, the precise
definition of frailty is an evolving one, but it is generally defined as an age-related
cumulative decline in physiologic reserve across multiple systems. With the aging global
population, frailty is almost unavoidable53,54. Frailty in the general population, however,
markedly differs from the hospitalized population. In community-dwelling persons
between ages 65 to 90 years, prevalence is typically <30%55. In the acute care hospital
setting, the prevalence of frailty has been estimated to be up to 80% in older
patients56,57.

Not only is frailty pervasive, but it is also an important prognostic factor for adverse
health outcomes in many diseases. In older, nonsurgical patients, this phenotype is
well-studied. Recently, a large cohort study developed a hospital frailty risk score based
on the International Statistical Classification of Diseases and Related Health Problems,
Tenth Revision (ICD-10) diagnostic codes and found frailty was significantly associated
with 30-day mortality and 30-day readmission58. This paper represents one of the many
studies that have demonstrated frailty is a predictor for many adverse health outcomes,
including disability, falls, delirium, hospitalization, and mortality56,58–60.

Similarly, frailty is equally, if not more, prevalent in the surgical patient population. In a
study of 594 patients presenting for elective surgical procedures, 42% of patients had
some element of frailty present61. Thoracic surgical candidates are no exception; in fact,
they are one of the most frail surgical populations, as demonstrated by a recent
prospective cohort study of 125 patients that found two thirds of patients had at least
one frailty trait, with 12% meeting 3 or more criteria of frailty62. Surgery in the already
frail population introduces an additional level of stress, and therefore opportunity for
morbidity. Emerging research has established frailty as a strong predictor of adverse
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outcomes and is associated with at least a 2-fold increase in operative mortality,
postoperative complications, and rates of readmission in the elderly undergoing surgery
for cardiac, colorectal, vascular, and orthopedic procedures

61,63,64.

However, recent

studies have also shown that frailty-related adverse outcomes are not limited to the
elderly. A 2019 multi-centre prospective cohort study in adult emergency surgical
admissions found that worsening frailty at any age is associated with significantly poorer
patient outcomes, including increased length of hospital stay, 30-day readmission and
30-day mortality65.

Despite the importance of frailty and its impact on health outcomes, there is no
consensus on the standard of measurement, much less frailty assessment in the
preoperative setting. Surgeon impressions, although potentially accurate, lack reliability
and reproducibility66,67. A recent review on the assessment of frailty in the acute care
setting found that two thirds of articles on these subject identified participants as frail
without actually measuring frailty59. The ones that did had great variability in the tools
used59. Over the past 20 years, dozens of frailty assessment instruments have been
developed for the purpose of risk stratification. Although the approaches may differ, all
seek to capture some element that suggests decreased physiologic reserve. The
majority of these instruments fall into two predominant models. The first is the frailty
phenotype instrument initially described by Fried et al.68, where motor and activity
measures are aggregated into a score that spans from robust to frail. The second is the
frailty index, as described by Mitnitski et al.69, where co-morbidities, social factors, and
psychological decline measures are incorporated into an index; the higher the number
of conditions, the higher the frailty score70 (Table 2).
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Table 2 – Comparison of frailty assessment tools
Instrument

Type

Number of
items

Domains

Fried Phenotype68

Ordinal (0-5, ≥3 frail)

5

Physical

FRAIL Scale71

Ordinal (0-5, ≥3 frail)

5

Physical

Frailty Index69

Continuous (combination
of tests and self-report)

92

Physical,
psychosocial,
social

Edmonton Frail Scale72

Ordinal (0-17 score with 5
levels from not frail to
severe frailty)

11

Physical,
psychosocial,
social

Clinical Frailty Scale Canadian Study of
Health and Aging73

Ordinal (1-7 levels from
robust to complete
dependence)

70

Physical,
psychosocial

11-factor Modified
Frailty Index74

Dichotomous (frail or not
frail)

11

Physical

5-factor Modified Frailty
Index75

Dichotomous (frail or not
frail)

5

Physical

Currently, there is no standardized frailty assessment tool used perioperatively. In fact,
despite guidelines from specialty societies and national institutions that recommend
frailty assessment as best practice76,77, there is currently little evidence to suggest that
frailty assessment is routinely conducted in the preoperative setting78. One barrier is the
lack of clarity on which measurement tool to use – there are more than 50 frailty
instruments or proxy measures described in the literature that have been used in clinical
settings79,80. Examples of frequently used frailty instruments include the Fried Scale 68,
FRAIL scale71, Frailty Index (a model based on accumulating deficits)69, Edmonton Frail
Scale (a reduced version of the accumulating deficits)72, and the National Surgical
Quality Improvement Program (NSQIP) Modified Frailty Index (mFI)81 (Table 2). Other
well-studied approaches of single physical performance metrics include the 6-min walk
test82, hand-grip strength83, and gait speed84.
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While predictive accuracy is fundamental to choosing a risk stratification instrument, any
frailty tool used in clinical practice must also be simple, accessible, and feasible. Within
the surgical literature, there is limited data formally assessing the feasibility of frailty
instruments. Even more sparse is the evidence supporting, using, and validating frailty
assessment tools in thoracic surgery patients85 - a group with high rates of frailty62.
Incorporating risk stratification of this patient population into a standard preoperative
work-up is clearly feasible, as demonstrated by Hirpara et al. in a 2019 study that
investigated frailty assessment in the thoracic surgery population using various scales86.
Of the 8 frailty measurements used in this study, including physiotherapy tests (6-min
walk, gait speed, hand-grip strength), risk stratification (Charlson Comorbidity Index
(CCI), Revised Cardiac Risk Index (RCRI), modified Frailty Index), and quality of life
questionnaires, Hirpara et al. reported 100% completion rate for the frailty indices86.
Furthermore, despite a small sample size and heterogenous population of 40 patients,
they found that the mFI (11-factors) was shown to approach significance (P = 0.06) in
predicting post-operative complications86.
Esophagectomy patients – especially those with esophageal cancer – are woefully
understudied in the context of frailty. Despite the existence of over 50 frailty assessment
tools and proxies, there remains a gap in the literature with respect to how frailty
impacts patients undergoing esophageal resection. First, there are currently no accurate
estimates of the incidence of frailty within this patient population. Two prospective
observational cohort studies designed to address this question are still ongoing – a
study of 60 patients based in Denmark is due to conclude in 202287, another study by
the Cleveland Clinic of 360 patients (esophagectomy and lobectomy combined) will be
completed in 202388. To date, only a handful of established frailty measures have been
studied in the context of esophagectomy outcomes. In its simplest form, frailty as
measured by physiologic metrics has shown promising results in terms of identify
patients at risk for morbidity and mortality. In a prospective study of 61 patients, Chen et
al. found that esophagectomy patients with weak hand-grip strength prior to operation
had exceedingly high rates of morbidity within six months such that 100% of patients
with grip strength less than 20kg experienced complications as compared with only 20%
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in those with grip strengths over 40kg89. Another recent study of 77 patients by Tang et
al. created a brand-new scale using a composite of 4 different physiologic metrics,
including upper body strength (grip strength), lower body strength and balance (30second chair sit-stands), muscle mass (psoas muscle area to height ratio), and
cardiopulmonary endurance (6-minute walk distance)90. Their quantitative
“Esophagectomy Vitality Index” appeared to outperform the established 11-factor
NSQIP mFI in predictive accuracy for post-esophagectomy morbidity and mortality90.
Far from discrediting the mFI, Tang et al.’s study of only 77 patients and low rate of
desired outcomes (1 mortality, 1.3%; 18 complications, 23%) raises further interest in
just how much value the mFI can provide for the esophageal patient population. This is
because physiologic measurements are time-consuming and require adequate space,
special equipment or personnel, which can be a barrier to adoption and completion in
the clinical setting86. The mFI, on the other hand, can be readily obtained from available
clinical information in both a prospective and retrospective manner. Using the NSQIP
database, which collects patient data from across North America and Europe, the mFI
has been robustly applied to a wide range of operations. Due to the low number of
esophageal cancer patients in general, and even lower still the ones amenable to
surgery, the mFI needs to be similarly evaluated in esophagectomy patients using the
NSQIP database.

1.4.1.1 American College of Surgeons National Surgical Quality
Improvement Program (NSQIP) modified Frailty Index (mFI)

The Modified Frailty Index developed by the American College of Surgeons National
Surgical Quality Improvement Program is one of many scales that exist to measure
frailty. The beauty of the mFI is its simplicity and ease of use, as demonstrated by
Hirpara et al. in their 2019 study where they demonstrated a 100% completion rate
using the mFI as part of a pre-operative frailty assessment for 40 patients with lung or
esophageal cancer.
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Originally, the NSQIP mFI contained 11 variables (mFI-11) that mapped to variables
from the Canadian Study of Health and Aging Frailty Index (CSHA-FI) (Table 3), a 70item scale based on the concept of accumulating clinical deficits, which has been shown
to be effective in predicting morbidity and mortality in patients73,91,92. The index is
obtained by dividing the total number of positive variables present by 11 74. Due to the
simplicity of the mFI, it has since gained interest in the academic surgical community as
a viable contender for preoperative risk stratification.

Velanovich et al. in 2013 were one of the first groups to hypothesize that preoperative
frailty, defined using the NSQIP mFI, could predict postoperative morbidity and
mortality74. Using NSQIP data from 971,434 patients undergoing multiple different
domains of subspecialty surgeries obtained over a 4 year period (2005-2009), they
demonstrated that there was a stepwise increase in risk of both mortality and morbidity
for each unit increase in mFI 74. This applied to a wide range of surgical subspecialties.
Since then, similar findings have been replicated in NSQIP studies within surgical
disciplines such as otolaryngology93, urology94, general surgery81,95, orthopedic
surgery96, and more. A 2018 meta-analysis of 16 studies – the first paper to synthesize
the evidence across multiple surgical specialties – demonstrated mFI-11 as a
prognostic indicator that strongly correlates with post-surgical morbidity and morality.
Frail patients (patients with mFI scores above zero) were twice as likely to have major
complications (RR 2.03, 95%CI 1.26-3.29; P = 0.004) and 4 times more likely to die (RR
4.19, 95% CI 2.96-5.92; P < 0.001) compared to non-frail patients97.
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Table 3 - NSQIP mFI-11 preoperative risk factors mapped to items of CSHA-FI
1

2

3
4
5
6

7
8

NSQIP mFI-11
Functional health status before surgery*
- partially dependent
- totally dependent

Diabetes mellitus*
- noninsulin
- insulin
History of severe COPD*
Current pneumonia
Congestive heart failure within 30 days
before surgery*
Cardiac problems
- History of myocardial infarction
within past 6 months before surgery
- Previous percutaneous coronary
intervention or percutaneous
- Previous cardiac surgery
- History of angina within 1 month
before surgery
Hypertension requiring medication*
Impaired sensorium

9
History of transient ischemic attack
10 Cerebrovascular accident or stroke with
neurologic deﬁcit
11 History of revascularization or amputation
for peripheral vascular disease
Rest pain or gangrene

CSHA-FI
Changes in everyday activity
Problems with getting dressed
Problems with bathing
Problems with carrying out personal
grooming
Problems with cooking
Problems with going out alone
History of diabetes mellitus

Lung problems
Respiratory problems
Congestive heart failure
Myocardial infarction
Cardiac problems

Arterial hypertension
Clouding or delirium
History relevant to cognitive impairment or
loss
Family history relevant to cognitive
impairment
Cerebrovascular problems
History of stroke
Decreased peripheral pulses

CSHA-FI = Canadian Study of Health and Aging frailty index; COPD - chronic obstructive pulmonary
disease; NSQIP - National Surgical Quality Improvement Program.
*mFI-5 factors
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Within the NSQIP literature, esophagectomy patients are understudied. Hodari et al.
published one of the first studies looking at mFI-11 score and adverse outcomes in
esophagectomy patients. Using a cohort of 2095 patients who underwent an
esophagectomy between 2005 to 2010, they found that among the parameters
associated with postoperative outcomes, frailty was significantly associated with risk of
perioperative morbidity and mortality. The incidence of perioperative mortality
incrementally increased with the frailty score, with mortality only 1.8% among patients
with a frailty score 0 vs. 23.1% among those patients with a frailty score 5 (P = 0.001) 98.
It should be noted that the maximum score was only 5 out of 11, indicating there may be
room for further simplification of this index. Three other studies subsequently confirmed
the association between higher mFI score and mortality81,98, as well as major
postoperative complications, and prolonged length of stay in hospital99.

In the last decade however, many NSQIP variables have been modified or removed, as
previous literature has shown that frailty indices with as few as 10 variables are
reliable100. In 2011, the reporting of some preoperative patient comorbidities, such as
pneumonia, cardiac problems, and a history of transient ischemic attack, was made
optional. Starting in 2012, NSQIP stopped recording some variables altogether, making
this the last year containing all 11 comorbidities making up the original mFI-11. Gani et
al. highlighted this problem of missing data, questioning the capability of using the 11factor mFI within clinical evaluation and for future research101. As of 2015, only 5 of the
original 11 factors remained. The 5 remaining variables are: functional status, diabetes,
congestive heart failure, hypertension requiring medication, and severe COPD 102.

This data issue prompted a transition from the 11-factor to the 5-factor Modified Frailty
Index (mFI-5). Several studies have attempted to validate the value of this new scale for
surgical risk stratification in a variety of operations. In a 2017 publication, Subramniam
et al. was to the first to directly compare mFI-5 to its 11-factor predecessor. They
demonstrated that mFI-5 was an equally effective predictor for mortality, post-operative
complications, and unplanned 30-day readmission across all sub-specialty surgeries,
except for cardiac and vascular surgery103. Since then, the 5-factor mFI has been used
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to successfully predict complications in several surgical subspecialties, including
thoracic surgery75,104–106. However, within thoracic surgery, there have been no studies
specifically examining the value of mFI-5 in esophagectomy outcomes.

1.4.2 Sarcopenia
The plethora of frailty assessment tools designed to quantify physical and psychosocial
parameters as a proxy for physiologic reserve still seem to fail to capture or account for
the impact of functional status. In this respect, morphometric analyses, such as
sarcopenia, may offer unique insight into measures of patient health that can affect
post-surgical outcomes. Sarcopenia is a term first introduced in 1989 by Irwin
Rosenberg; it stems from the Greek words “sarx” meaning flesh and “penia” meaning
loss or poverty107. In medicine, sarcopenia was originally defined by the 2010 European
Working Group on Sarcopenia in Older People (EWGSOP) as the presence of low
muscle mass and low muscle function (low muscle strength or low physical
performance)53. In 2019, the revised EWGSOP2 operational definition identifies
probable sarcopenia with presence of low muscle strength and confirms the diagnosis
with low muscle quantity or quality. If there is presence of low physical performance,
sarcopenia is considered severe108. This shift in emphasis from muscle mass to muscle
strength is relatively new and not yet widely adopted in research. This is likely because
assessments of muscle strength, such as grip strength or chair stand test, are not
collected as part of routine clinical assessment. Given the retrospective nature of most
studies on sarcopenia, this parameter has not been extensively studied or incorporated
into more accessible measurements of muscle mass, such as of skeletal muscle area
which is derived from CT or magnetic resonance imaging (MRI). Nevertheless, much
literature has been written about using muscle mass alone as a parameter for
diagnosing sarcopenia.

Sarcopenia is part of the normal aging process, where muscle loss starts at 30 years of
age and accelerates after 70 years54. In the general population, estimated prevalence in
those between 60 to 70 year old is 5 to 13%; this increases to 11 to 50% in people over
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80 years of age53. Although it is primarily associated with aging, sarcopenia is not
exclusive to the elderly. Malignancy is one of the most notable pathological conditions
that promotes muscle atrophy109 as patients experience malnutrition, decreased activity
levels, and cachexia. One systematic review of 35 articles across a wide range of
cancers found that 38.6% of adult cancer patients awaiting therapy were sarcopenic 110.
Others show the prevalence of sarcopenia differ widely from 14% to 78.7% depending
on the cancer diagnosis111.

Over and over again, sarcopenia has been found to be an independent prognostic
factor for reduced survival. It has been linked to morbidity and mortality in various solid
tumours, including breast112, colorectal113, pancreatic114, esophageal115 and other
gastrointestinal cancers116. Furthermore, in the surgical cancer population, sarcopenia
is significantly and independently associated with post-operative complications,
chemotherapy-induced toxicity and poor survival110. For esophageal cancer in the
context of surgical resection, the literature on the association between sarcopenia and
post-operative outcomes is only emerging over the last 10 years. In the esophageal
cancer population, the role of sarcopenia remains controversial, as findings are often
inconsistent. This is in large part because, despite a clear definition, there is no
consensus on diagnostic criteria or standardized measurement until very recent
recommendations by the updated guidelines from EWGSOP2. There is considerable
variation within sarcopenia literature, as the number of reports relating to body
composition assessment in patients undergoing surgical resection for esophageal
cancer continue to rise. As such, meta-analyses attempting to synthesize the existing
body of work contain significant heterogeneity in terms of surgical approach and
technique (i.e., abdominal vs. thoracic, open vs. minimally invasive), histology (i.e.,
adenocarcinoma, SCC), neoadjuvant treatments, clinical stages, and sarcopenia criteria
(i.e., psoas vs. skeletal muscle index).

Although the measurement of muscle mass in sarcopenia has been largely established
using CT measures, there is still much variation. For example, some studies use lean
psoas area (LPA) – the total area of the psoas muscle in a cross-sectional CT scan
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measured at the 3rd or 4th lumbar vertebrae (L3 or L4) normalized by height. Others use
the Skeletal Muscle Index (SMI, cm2/m2) – calculated by the formula total area of
skeletal muscle measured on CT at L3 (cm2) divided by height (m) squared117. The SMI
is the predominant method of calculation because it provides a quantifiable,
reproducible and objective measure of sarcopenia that has been found to correlate both
with body composition and cancer patient prognosis118. However, defining parameters
for body composition continues to be a challenge since there is no universally agreed
upon cut-off threshold for sarcopenia. As such, interpretation of sarcopenia literature
must be approached with a nuanced eye.

Perhaps not surprisingly, in the studies examining the impact of sarcopenia on
esophageal cancer resection, results with respect to postoperative morbidity varies
considerably. A 2013 study by Sheetz et al. – one of the early forays into sarcopenia
and esophagectomy outcomes – examined a cohort of patients undergoing transhiatal
esophagectomy for cancer. They did not find LPA to be a significant factor in developing
major morbidities, such as pulmonary complications119, which was similarly reported by
Nakashima et al. who used Skeletal Muscle Index (SMI) for their sarcopenia
assessment120. However, several subsequent Japanese studies have since refuted
these findings with respect to postoperative pulmonary complications, where the risk in
sarcopenic patients defined using SMI were found to be 2- to 4-fold compared to their
non-sarcopenia counterparts. Additionally, the incidence of prolonged ventilatory
support, reintubation for respiratory failure, pleural effusions, and pneumonia were
higher in patients with sarcopenia121–125 – suggesting that the presence of sarcopenia
appeared to be an independent predictor of pulmonary complications. Two metaanalyses also support these findings, one of which found in their subgroup analysis that
sarcopenic patients were almost 2 times more likely to experience postoperative
pneumonia126. Interestingly, when it comes to non-pulmonary complications,
particularly anastomotic leaks, there is virtually no evidence to support that sarcopenia
is a significant risk factor121–128.
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The results with respect to post-surgical mortality are also varied. One study found that
sarcopenia may not be a significant predictor of overall survival or disease free survival
in patients receiving neoadjuvant chemoradiation; however, in patients not receiving
neoadjuvant therapy, both overall and disease free survival are better in the absence of
sarcopenia119. Few studies assess mortality however, the ones that do have not
demonstrated sarcopenia as a significant risk factor for short term survival (in-hospital
or 30-day) 126,128,129. Where long term survival is concerned, sarcopenia perhaps
warrants more consideration. A meta-analysis by Deng et al. which examined 11 cohort
studies consisting of 1520 patients who underwent esophagectomy for esophageal
cancer of various stages found that patients with sarcopenia had a significantly lower 3year as well as 5-year overall survival compared to those without130. Similarly, Boshier
et al. also reported lower long term survival in sarcopenia patients overall126. However,
a more recent meta-analysis from 2020 also with 11 studies, but representing 1979
patients, found no difference in mortality rates between patients with and without
sarcopenia127.

Despite the inconclusive evidence with respect to post-operative outcomes, sarcopenia
has proven to be an important measure of patient health. It is also clear that, just like
frailty indices and other instruments designed to assess functional capacity, sarcopenia
still provides an incomplete picture. Its utility as a risk stratification tool for esophageal
cancer patients undergoing oncologic resection certainly warrants further investigation.
Given the limited evidence to support the predictive superiority of a single instrument,
perhaps there are yet other ways to improve on the existing methods.

1.5 Hypothesis and objectives
To the best of our knowledge, there have been no studies thus far specifically
examining the predictive value of mFI-5 in post-esophagectomy outcomes for
esophageal cancer patients, nor have there been studies directly comparing frailty
versus sarcopenia in the same cohort of patients. Given the prevalence of malnutrition,
sarcopenia, and frailty, as well as the high rate of morbidity and mortality associated
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with esophageal cancer and surgical resection, we aim to further investigate mFI-5 and
sarcopenia to aid both patients and health care providers in making the most informed
treatment decisions.

Pre-operative identification of factors associated with post-esophagectomy morbidity
may provide us an opportunity for patient optimization to minimize negative outcomes.
The current literature does not provide evidence to support the ideal way to identify
patients with poor physiologic reserve undergoing esophagectomy. We hypothesize that
frailty and or/sarcopenia measurement may be useful markers for increased risk of postoperative morbidity and mortality. This thesis investigates two tools – the NSQIP 5Factore modified frailty index and sarcopenia as measured by skeletal muscle index
using total skeletal muscle area – to understand their association with post-operative
outcomes in patients undergoing esophagectomy for esophageal cancer.
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Chapter 2 – NSQIP 5-Factor Modified Frailty Index is Associated with Morbidity
not Mortality after Esophagectomy for Esophageal Cancer
2.1 Introduction
Esophageal cancer is one of the most highly lethal gastrointestinal tract malignancies. It
is 7th in incidence and 6th in cancer mortality worldwide1. The incidence of esophageal
cancer has increased sharply over the past few decades. An esophagectomy is the
cornerstone of treatment and historically associated with significant perioperative
morbidity and mortality12,13. The increased risk of postoperative complications is
compounded by malnutrition caused by dysphagia and cancer cachexia, resulting in
physiological and functional compromise.

Frailty is a multidimensional state of increased vulnerability and not limited to the
elderly. Frailty at any age is associated with significantly poorer post-operative patient
outcomes, including increased length of hospital stay, readmission and mortality 65.
Thoracic surgery patients have a high proportion of frailty, as demonstrated by a recent
prospective cohort study of 125 patients that found two thirds of patients had at least
one frailty trait, with 12% meeting three or more criteria of frailty62.

The mFI derived from the variables of the American College of Surgeons National
Surgical Quality Improvement Program (ACS NSQIP) is one of many scales that exist to
measure frailty. Originally, the NSQIP mFI contained 11 variables that mapped to
variables from the Canadian Study of Health and Aging Frailty Index (CSHA-FI) (Table
2), a 70-item scale based on the concept of accumulating clinical deficits, which has
been shown to be effective in predicting morbidity and mortality in a wide variety of
patient populations73,91,92. In 2015, the 11-factor index (mFI-11) was simplified to only
five factors (mFI-5) after eliminating factors where reporting was optional and therefore
inconsistently recorded (Table 3). In the original mFI-11, the incidence of postoperative
mortality in esophagectomy patients incrementally increased with frailty score 98.
Further, mortality among non-frail patients was only 1.8% compared to 23.1% among
patients with a frailty score 5 (P = 0.001)98. Since the simplification of the modified frailty
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index, however, the mFI-5 has not been re-examined in the esophagectomy population.
A better understanding of how the mFI-5 is associated with surgical outcome is
imperative to define the utility of this frailty index as a risk stratification tool in this patient
cohort.

In this study, we used the ACS NSQIP 5-factor modified frailty index to investigate the
association between frailty and postoperative severe complications and mortality in
patients undergoing esophagectomy for esophageal cancer. We hypothesized that
frailty would be associated with a higher rate of complications and death.

2.2 Methods
We obtained data on all patients who underwent an esophagectomy between 20162018 from the ACS NSQIP Participant User File (PUF)102. The NSQIP PUF is a Health
Insurance Portability and Accountability Act (HIPAA)-compliant data file containing
postoperative 30-day patient data collected from over 700 hospitals largely in North
America, with a few participating locations in Australia, Europe, Asia, and the Middle
East. The database incorporates more than 270 variables including demographics,
surgical proﬁles, comorbidities, and preoperative and intraoperative variables. Data are
captured by trained surgical clinical reviewers both in hospital and after discharge

102.

Data are captured for the first 30 post operative days102. In order to obtain complete
data on this patient population, both the main PUF and procedure-specific
esophagectomy PUF were used. The procedure-specific esophagectomy PUF
contained information on neoadjuvant treatment status and pathologic diagnosis, which
were not available in the main PUF. The years 2016-2018 were selected because this
period represents the years for which the procedure-specific esophagectomy PUF was
available. Patients were included if they were over 18 years of age, underwent an
esophagectomy for esophageal cancer or dysplasia, and had complete records for the
mFI-5 ﬁelds and outcomes of interest.

22

The mFI-5 frailty index consists of 5 non-overlapping clinical conditions: 1) hypertension
requiring medication, 2) diabetes mellitus requiring treatment with oral agents or insulin,
3) history of severe COPD; 4) functional status, and 5) congestive heart failure (CHF) in
30 days before surgery 102. Functional status was broken down into independent,
partially dependent, or totally dependent – a point was counted for this variable if the
patient was partially or totally dependent. The mFI score was calculated for each patient
by adding the number of variables present in NSQIP for each patient, with 0–5 total
points possible. In keeping with other studies using mFI, we chose to not assess
weights to each factor to keep the determination of the FI as simple as possible 81,98,103.
Additional comorbidities were extracted from the database to provide a fulsome
description of the patient population. These included smoking, dyspnea, ventilator
dependent status, ascites, dialysis, disseminated cancer, open wound or wound
infection, chronic steroid use, more than 10% weight loss in last 6 months, bleeding
disorder, transfusion within last 72 hours, and preoperative sepsis (Table 6).

The primary outcome was the association between mFI-5 score and severe
postoperative complications within 30 days. Postoperative complications were
evaluated using the Clavien-Dindo classification system, with severe complications
categorized as grade IV based on the Clavien-Dindo grading criteria (Table 4). ClavienDindo grade IV complications are defined as those which are life-threatening and
therefore require management in the intensive care unit (ICU). Within NSQIP, we
considered the following complications grade IV: reintubation, ventilation >48hr, cardiac
arrest, myocardial infarction, renal failure requiring dialysis, stroke/CVA, and septic
shock. These complications were chosen either because of the known need to for an
ICU setting (e.g. vasopressor support for shock state in sepsis), or in accordance with
the clinical examples of complications grades proposed by the Clavien-Dindo
system131,132.
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Table 4 – Clavien-Dindo classification of surgical complications131 and
corresponding NSQIP categories102
Grade

Definition

I

Any postoperative complications that do not require interventions
- Superficial SSI, acute renal failure, renal insufficiency, neurologic
deficit/peripheral nerve injury

II

Postoperative complications requiring pharmacologic interventions
- Deep incisional SSI, organ/space SSI, wound
disruption/dehiscence, deep vein thrombosis, pulmonary
embolism, pneumonia, urinary tract infection, transfusion, sepsis

III

Postoperative complications requiring surgical, radiologic, or endoscopic
interventions
- Reoperation

IV

Life-threatening complications requiring intensive care unit management
- Ventilator >48 hr, reintubation/unplanned intubation, septic shock,
myocardial infarction, cardiac arrest, stroke/CVA, progressive renal
failure requiring dialysis

V

Complications leading to death

SSI = surgical site infection

Secondary outcomes included 30-day mortality, length of stay >30 days, return to the
operating room, and anastomotic leak. According to NSQIP, length of stay >30 days is
counted for patients who have a continuous stay in the acute care setting more than 30
days after surgery. Return to the operating room status is recorded to include all major
surgical procedures that required the patient to be taken to the surgical operating room
for intervention of any kind.

2.2.1 Statistical Analysis
The available data were described as means with standard deviations for normally
distributed continuous variables, medians with interquartile ranges for non-normally
distributed continuous variables, and frequencies with associated percentages for
categorical variables. Shapiro-Wilk normality test was used to determine normality of
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continuous variables: age, body mass index (BMI), total length of stay, and operation
duration.

Relationships between categorical variables were assessed using Pearson chi-squared
or Fischer’s exact test, where appropriate. Relationships between categorical and
continuous variables were assessed using one-way ANOVA or Kruskal-Wallis rank sum
test, where appropriate. Univariate logistic regression was used to determine the odds
ratio (OR) in unadjusted comparisons between higher mFI scores to mFI 0 for both
major postoperative complications and mortality.

Multivariate logistic regression was used to obtain an adjusted estimate of the
association between mFI score and outcomes of interest. Variables for inclusion were
chosen based on: 1) known clinical association with adverse surgical outcomes based
on existing literature133–136, or 2) a statistically significant relationship (p<0.10) with
increase mFI score based on univariate analysis. Variables included: age, sex, BMI,
American Society of Anesthesiology (ASA) classification, operative duration, emergency
surgery status, and neoadjuvant therapy status. Since only 7 patients (0.3%) had an
ASA of 1, this category was combined with ASA 2, which had 420 patients (16.4%).
This new ASA variable of 1+2 was used to compare against ASA 3 and ASA 4.

There was significant collinearity between preoperative chemotherapy and radiation, as
expected based on the current standard of neoadjuvant treatment. In order to avoid
over fitting the model, neoadjuvant therapy status was turned into a binary variable
where a positive status was recorded for patients who underwent either chemotherapy
or both forms of therapy. There was no significant collinearity between other variables in
the model (Figure 1).
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Figure 1. Pearson correlation coefficients for included NSQIP variables

Cases with missing data for any variable of interest were excluded on a case-by-case
basis. Although the missing data was presumed to be not at random, we did so
because the proportion of cases with missing data was very small compared to the total
sample size (<2%). Specifically for the data required to determine a mFI score, 5 cases
(0.19%) were excluded due to missing data. Readmission as an outcome was omitted
altogether since over one third of patients (832 of 2567, 32.4%) did not have data
recorded for this variable. A priori we planned to complete subgroup analysis based on
pathology, with the hypothesis that the impact of frailty on post-operative outcomes
would differ in patients with squamous cell carcinoma and adenocarcinoma. Due to the
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small number of patients with higher mFI scores, these analyses were significantly
underpowered and therefore not reported.

Results from regression analyses are presented as adjusted odds ratios along with 95%
conﬁdence intervals (CI) and P values. In all comparisons, a p-value of less than 0.05
was considered significant. All statistical analysis was carried out using SPSS software,
version 27 (IBM, Armonk, New York, USA).

2.3 Results
2.3.1 Patient Demographics
A total of 3,049,617 patients were included in the NSQIP database, between 20162018, 3,279 of whom underwent esophagectomy. Excluded patients totaled 712 and
were excluded for the following reasons: no data recorded for functional status (5), nonesophageal cancer or dysplasia on pathology (572 no malignancy, 51 other malignancy,
69 benign, 15 unknown pathology). In total, 2,567 cases were included in the final
analysis.

Patient demographics are outlined in Table 5. The median age was 65 (IQR 58-71) and
the median BMI was 27 (IQR 23.7-30.7). The majority were male (83.35%) with ASA 3
classification (76.3%). Adenocarcinoma (86.9%) was the most common diagnosis.
Calculated mFI-5 scores for all patients in the study sample ranged from 0 to 3; no
patients who underwent an esophagectomy had a frailty score of 4 or 5. The number of
patients with each mFI score were as follows: mFI 0 = 1103, (43%), mFI 1 = 982
(38.3%), mFI 2 = 435 (16.9%), and mFI 3 = 47 (1.8%). Increasing mFI scores were
associated on univariate analysis with increasing age (P <0.001), and BMI (P <0.001),
male sex (P<0.001), and not receiving neoadjuvant chemotherapy (P <0.001) and
radiation therapy (P <0.001) (Table 5). The most common comorbidity was
hypertension requiring medication (48.9%), followed by weight loss greater than 10kg in
the last 6 months (21.8%) (Table 6).
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Table 5 - NSQIP esophagectomy patient demographics by mFI-5 score
mFI-5 Score
Overall
N = 2567

0
N = 1103

1
N = 982

2
N = 435

3
N = 47

pvalue

65 [58-71]

62 [55-69]

67 [60-72]

68 [61-73]

69 [60.5-73]

<0.001

27
[23.7-30.7]
4 (0.2%)

25.8
[22.7-29]
1 (0.1%)

27.6
[24.4-31]
2 (0.2%)

28.8
[25.1-32.8]
1 (0.2%)

30.4
[25.9-34.2]
0 (0.0%)

Male

2138 (83.3%)

883 (80.1%)

851 (86.7%)

358 (82.3%)

46 (97.9%

Female

429 (16.7%)

220 (19.9%)

131 (13.3%)

77 (17.7%)

1 (2.1%)

2230 (86.9%)

939 (85.1%)

866 (88.2%)

384 (88.3%)

41 (87.2%)

0.16

272 (10.6%)

136 (12.3%)

92 (9.4%)

39 (9.0%)

5 (10.6%)

0.10

65 (2.5%)

28 (2.5%)

24 (2.4%)

12 (2.8%)

1 (2.1%)

0.97

Characteristic
Age (years)
Median [IQR]
BMI (kg/m2)
Median [IQR]
(Missing data)

<0.001

Sex
<0.001

Pathology
Adenocarcinoma
SCC
Dysplasia
ASA
Classification
1

7 (0.3%)

6 (0.5%)

1 (0.1%)

0 (0.0%)

0 (0.0%)

2

420 (16.4%)

256 (23.2%)

139 (14.2%)

25 (5.7%)

0 (0.0%)

1+2

427 (16.6%)

262 (23.7%)

140 (14.3%)

25 (5.7%)

0 (0.0%)

3

1959 (76.3%)

785 (71.2%)

771 (78.5%)

364 (83.7%)

39 (83.0%)

4

178 (6.9%)

55 (5.0%)

69 (7.0%)

46 (10.6%)

8 (17.0%)

3 (0.1%)

1 (0.1%)

2 (0.2%)

0 (0.0%)

0 (0.0%)

1,775 (69.1%)

853 (77.3%)

638 (65.0%)

254 (58.4%)

30 (63.8%)

27 (1.1%)

8 (0.7%)

12 (1.2%)

7 (1.6%)

0 (0.0%)

1,524 (59.4%)

730 (66.2%)

541 (55.1%)

228 (52.4%)

25 (53.2%)

31 (1.2%)

9 (0.8%)

14 (1.4%)

8 (1.8%)

0 (0.0%)

(Missing data)
Neoadjuvant
Chemotherapy
(Missing data)
Neoadjuvant
Radiation
(Missing data)

-

<0.001

<0.001
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Table 6 – NSQIP esophagectomy patient comorbidities by mFI-5 score
mFI-5 Score
Overall
N = 2567

0
N = 1103

1
N = 982

2
N = 435

3
N = 47

1,254 (48.9%)

0 (0.0%)

788 (80.2%)

421 (96.8%)

45 (95.7%)

Diabetes*

506 (19.7%)

0 (0.0%)

122 (12.4%)

342 (78.6%)

42 (89.4%)

Chronic obstructive
pulmonary disease*

203 (7.9%)

0 (0.0%)

66 (6.7%)

96 (22.1%)

41 (87.2%)

Functionally dependent*

20 (0.8%)

0 (0.0%)

6 (0.6%)

6 (1.4%)

8 (17.0%)

Congestive heart failure*

10 (0.4%)

0 (0.0%)

0 (0.0%)

5 (1.2%)

5 (10.6%)

Smoking

630 (24.5%)

290 (26.3%)

228 (23.2%)

97 (22.3%)

15 (31.9%)

Dyspnea

228 (8.9%)

68 (6.2%)

76 (7.7%)

69 (15.9%)

15 (31.9%)

Ventilator dependent

3 (0.1%)

2 (0.2%)

1 (0.1%)

0 (0.0%)

0 (0.0%)

Ascites

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

On dialysis

6 (0.2%)

2 (0.2%)

1 (0.1%)

2 (0.5%)

1 (2.1%)

Disseminated cancer

93 (3.6%)

43 (3.9%)

34 (3.5%)

12 (2.8%)

4 (8.5%)

15 (0.6%)

6 (0.5%)

8 (0.8%)

1 (0.2%)

0 (0.0%)

68 (2.6%)

22 (2.0%)

32 (3.3%)

13 (3.0%)

1 (2.1%)

560 (21.8%)

269 (24.4%)

199 (20.3%)

83 (19.1%)

9 (19.1%)

Bleeding disorder

93 (3.6%)

31 (2.8%)

37 (3.8%)

23 (5.3%)

2 (4.3%)

Transfusion ≥1 units
PRBCs in 72 hours
before surgery

6 (0.2%)

3 (0.3%)

2 (0.2%)

1 (0.2%)

0 (0.0%)

Preop sepsis

21 (0.8%)

11 (1.0%)

6 (0.6%)

3 (0.7%)

1 (2.1%)

Comorbidity
Hypertension on
medication*

Open wound/wound
infection
Steroid use for chronic
condition
>10% weight loss in last
6 months

2.3.2 Outcomes
Outcome distribution by mFI-5 score are displayed in Table 7. Clavien-Dindo grade IV
complications occurred in 14.6 % (374 of 2,567) of patients within 30 days. The
proportion of Clavien-Dindo IV complications increases significantly with higher mFI
scores (p<0.001). Overall mortality was 2.6% and was not significantly associated with
frailty on univariate analysis (p = 0.15). Frailty was, however, found on univariate
analysis to be associated with the following outcomes: length of stay (p=<0.001), length
of stay > 30 days (p=0.008), anastomotic leak (p<0.001), superficial SSI (p=0.025),
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organ space SSI (p=0.002), pneumonia (p<0.001), reintubation (p<0.001), prolonged
intubation (p<0.001), sepsis (p=0.043) and septic shock (p=0.002).

Multivariate logistic regression analyses controlling for age, sex, BMI, ASA class, total
operation time, emergency surgery status, and neoadjuvant status demonstrated
association between higher levels of frailty and complications (Table 8). Specifically,
patients with a mFI-2 had 1.53 times greater odds of Clavien-Dindo grade IV
complications, and those with mFI-3 had 2.35 times greater odds than those with an
mFI of 0.

Higher mFI scores had a larger proportion of patients who died within 30 days. Although
the odds ratio increased with higher mFI score, neither univariate nor multivariate
analyses for mortality reached significance.
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Table 7 – NSQIP Outcomes and corresponding mFI-5 score, N (%)
mF-5 Score
Complications
Clavien-Dindo IV
Mortality

Overall
N = 2567
374
(14.6%)

0
N = 1103
123
(11.2%)

1
N = 982
153
(15.6%)

2
N = 435

3
N = 47

p-value1

86 (19.8%)

12 (25.5%)

<0.001

67 (2.6%)

21 (1.9%)

29 (3.0%)

15 (3.4%)

2 (4.3%)

0.15

9 [7-12]

8 [7-11]

9 [7-13]

9 [7-14]

9 [7-14]

<0.0012

Length of stay
>30 days

123
(4.8%)

36 (3.3%)

56 (5.7%)

27 (6.2%)

4 (8.5%)

0.008

Return to OR

411 (16.0%)

128 (11.6%)

178 (18.1%)

98 (22.5%)

7 (14.9%)

<0.001

Anastomotic leak

357 (13.9%)

108 (9.8%)

160 (16.3%)

82 (18.9%)

7 (14.9%)

<0.001

Superficial SSI

120 (4.7%)

39 (3.5%)

48 (4.9%)

29 (6.7%)

4 (8.5%)

0.025

Deep SSI

28 (1.1%)

7 (0.6%)

14 (1.4%)

7 (1.6%)

0 (0.0%)

0.19

Organ space SSI

262 (10.2%)

88 (8.0%)

106 (10.8%)

61 (14.0%)

7 (14.9%)

0.002

Pneumonia

344 (13.4%)

115 (10.4%)

146 (14.9%)

72 (16.6%)

11 (23.4%)

<0.001

Reintubation

282 (11.0%)

87 (7.9%)

119 (12.1%)

66 (15.2%)

10 (21.3%)

<0.001

44 (1.7%)

19 (1.7%)

16 (1.6%)

7 (1.6%)

2 (4.3%)

0.49

226 (8.8%)

75 (6.8%)

95 (9.7%)

46 (10.6%)

10 (21.3%)

<0.001

27 (1.1%)

7 (0.6%)

11 (1.1%)

7 (1.6%)

2 (4.3%)

0.052

16 (0.6%)

5 (0.5%)

6 (0.6%)

5 (1.1%)

0 (0.0%)

0.46

DVT

65 (2.5%)

20 (1.8%)

30 (3.1%)

15 (3.4%)

0 (0.0%)

0.12

Stroke/CVA

4 (0.2%)

2 (0.2%)

1 (0.1%)

1 (0.2%)

0 (0.0%)

0.84

Myocardial
infarction

23 (0.9%)

3 (0.3%)

6 (0.6%)

12 (2.8%)

2 (4.3%)

<0.001

Cardiac arrest

Length of
hospital stay
(days)
Median [IQR]

Pulmonary
embolism
Prolonged
ventilation >48hr
Acute renal
failure
Progressive renal
failure

43 (1.7%)

15 (1.4%)

16 (1.6%)

11 (2.5%)

1 (2.1%)

0.34

Bleeding
requiring
transfusion

291 (11.3%)

113 (10.2%)

109 (11.1%)

62 (14.3%)

7 (14.9%)

0.13

Sepsis

130 (5.1%)

41 (3.7%)

60 (6.1%)

26 (6.0%)

3 (6.4%)

0.043

Septic shock

138 (5.4%)

43 (3.9%)

55 (5.6%)

34 (7.8%)

6 (12.8%)

0.002

C. difficile
infection

47 (1.8%)

16 (1.5%)

18 (1.8%)

11 (2.5%)

2 (4.3%)

0.22

SSI = surgical site infection; CVA = cerebral vascular event; DVT = deep vein thrombosis
1
2

Pearson's Chi-squared test; Fisher's exact test
Kruskal-Wallis rank sum test
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Table 8 – Adjusted Odds Ratio of Clavien-Dindo IV complications for mFI-5
score and covariates of multivariate logistic regression
Variable

Odds ratio (P; 95% CI)

mFI 1 (vs. 0)

1.28 (0.070; 0.98 - 1.68)

mFI 2 (vs. 0)

1.53 (0.011; 1.10 - 2.11)

mFI 3 (vs. 0)

2.35 (0.017; 1.16 – 4.74)

ASA Class 3 (vs. 1+2)

1.84 (0.002; 1.25 – 2.70)

ASA Class 4 (vs. 1+2)

2.10 (0.006; 1.24 – 3.57)

Age

1.01 (0.128; 0.99 – 1.02)

Sex

1.22 (0.186; 0.91 – 1.63)

BMI

0.99 (0.390; 0.97 – 1.01)

Operative duration

1.00 (0.000; 1.00 – 1.00)

Emergency surgery

2.83 (0.246; 0.49 – 16.34)

Neoadjuvant therapy

0.62 (0.000; 0.49 – 0.078)

2.4 Discussion
The impact of frailty as a risk factor is difficult to assess for cancer patients undergoing
esophageal resection. In this study, we investigated the association between the NSQIP
mFI-5 and 30-day post-esophagectomy outcomes in those with dysplasia and malignant
esophageal pathologies. These outcomes included severe ICU-level complications,
mortality, length of stay >30 days, return to the operating room for any reason, and
anastomotic leak. Although higher mFI-5 score was associated with significantly higher
odds of severe complications, and to a lesser extent, return to the operating room and
anastomotic leak, the same level of significance could not be said about mortality and
prolonged hospital stay, although there is a trend towards increased risk.

Patient selection is crucial to reducing the inherent risk of surgery in the oncology
patient population. How the stress of surgery affects patients is multifactorial; having an
accurate perception of surgical risk is important for treatment planning. Risk calculators
for preoperative stratification of surgical patients have been used for decades - the
American Society of Anesthesiologists physical status (ASA-PS) classification,
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developed over 70 years ago, is still the most widely used tool for risk assessment by
surgeons and anesthesiologists. Although the ASA classification has good predictive
power for complications, mortality, and length of stay despite being highly subjective
and moderate inter-rater reliability137, the operative risk for a high-risk patient
undergoing bunion surgery is quite different than the operative risk for the same patient
undergoing an esophagectomy. Inaccurate estimations of morbidity and mortality can
lead to inadequate information being provided during the consent process and poor
resource allocation in the postoperative period.

Emerging research has established frailty as a strong predictor of adverse outcomes
and is associated with increased operative mortality, postoperative complications, and
rates of readmission61,63,64,73. Several frailty assessment tools have been developed that
focus on simple motor and activity measures. Both grip strength 138 and gait speed139
have been proposed as useful single markers of physical frailty, in addition to being
components of validated frailty scales, such as the Fried Frailty Phenotype 68 and FRAIL
scale140,141. In clinical practice, the application of these frailty assessment tools have
been limited, likely because of the resources required to obtain physical measurements.
More complex risk stratification tools, such as the Edmonton Frail72 and CSHA-FI73,91,
take into account both physical and psychosocial metrics in an attempt to produce
results with more granularity. Although the 70-item CSHA-FI is a well validated frailty
assessment tool73,91, the sheer scope of its variables and time constraints in a clinical
setting likely remains a barrier to routine adoption for surgical patients.

For esophageal cancer patients undergoing resection, there are currently no wellvalidated esophagectomy-specific risk stratification tools, despite several attempts over
the years142–145. The variability in surgical approach, preoperative nutritional status,
neoadjuvant therapy, and extent of disease likely all contribute to the challenges in
developing a risk calculator in this patient population. In 2016, the Society of Thoracic
Surgeons (STS) revised their model for perioperative risk for esophagectomy in cancer
patients. Using the STS General Thoracic Surgery Database of over 4000 patients, they
developed a multivariable risk model for major morbidity, mortality, as well as a
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combined morbidity and mortality composite outcome. The covariates were a
comprehensive set of variables, including patient characteristics, surgical approach, and
oncologic factors. Although the c-statistic for the STS model was 0.71 for morbidity and
0.63 for mortality144, this was produced from an exhaustive list that is impractical for use
in a clinical setting. Since this list includes many of the same esophagectomyassociated factors identified by the much simpler NSQIP mFI, such as hypertension,
diabetes, and cardiovascular problems, the mFI could represent a much more versatile
tool that achieves similar results.

The original NSQIP mFI-11, based on the validated 70-item CSHA-FI, has been studied
in several surgical population, including thoracic surgery9,24–26. The mFI-11 generated a
frailty score from 11 variables that could be calculated using information easily obtained
from existing clinical documentation, making it an attractive option in the clinical setting.
It was suggested that fewer NSQIP data points in a limited model (i.e. five variables)
could produce comparable risk assessment compared to a full model (i.e. 21
variables)146. As such, the mFI-11 was simplified to the mFI-5 with five variables in
2015. Interestingly, the mFI-5 still retained many of the same esophagectomyassociated risk factors identified by the STS risk model. Compared to the STS model,
the c-statistic of both the mFI-11 and mFI-5 in thoracic surgery patients were
comparatively higher for morbidity (0.73) and mortality (0.77)103. Although not
esophagectomy-specific, this raised the possibility of the mFI having similar predictive
values if applied to the esophagectomy cohort.

Overall, application of any version of the mFI in esophagectomy patients has been
limited. In one study of the mFI-11 using NSQIP data, Hodari et. al found those with
frailty had a high and statistically significant risk of death within 30 days (OR 31.84,
p=0.015) compared to those without frailty98. Despite the fact that mortality was
proportionally similar between their study and ours (3.5% vs. 2.6%), mFI-5 was no
longer significantly associated with mortality in either the univariate or multivariate
analysis, regardless of score. In contrast, mFI-5 was still associated with a number of
adverse outcomes. In our multivariate analysis, mFI 2 and 3 reached significance for
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Clavien-Dindo grade IV complications (p=0.027), while mFI 1 and 2 reached
significance for anastomotic leak (p<0.000) and return to the operating room (p<0.000).

While meaningful statistical analysis of adverse outcomes is hindered by both the small
sample size of mFI 3 patients (47 of 2567, 1.8%) and the small proportion of patients
who experienced them, this is also likely a testament to the stringent patient selection
for this surgery. No one in our study had an mFI score over three, meaning patients who
had four or five of the mFI comorbidities were not offered surgery. Simplifying mFI-11 to
mFI-5 may have reduced the burden of data collection, but it may have also impaired
the ability to examine frailty specific to esophagectomy patients. The simplified mFI-5
may no longer be nuanced enough to explore vulnerabilities specific to esophageal
cancer and esophagectomies, thereby underestimating the true markers of frailty in
these patients. In a study that specifically addressed risk factors for anastomotic leak
after esophagectomy for cancer using NSQIP data, Hall et al. discovered four variables
that were independently associated with anastomotic leak147. Only the diabetes variable
is part of the mFI-5. More recently, Gray et al. applied the mFI-5 to a cohort of 240
patients at their local institution and found it lacking in discriminatory performance for
severe and all complications, with c-statistics of only 0.52 and 0.51 respectively. It
should be noted that based on our experience with the small proportion of patients in
the higher mFI score categories as noted above, validation of the results in a much
larger sample size is likely warranted. Ultimately, a surgeon’s decision to operate is
multifaceted; it is possible those with higher frailty scores (i.e., mFI 3) possess or lack
other qualities unaccounted by mFI-5 that make the surgeon believe they would make
good surgical candidates.

The strengths of our study include a large sample size with consistent reporting of
granular details from a multicentered cohort and a focus on severe clinically significant
complications in the first and only study to use mFI-5 in esophagectomy patients. There
are, however, some limitations of our study largely due to the nature of NSQIP data and
the difficulties in defining frailty. First, given the small number of mFI 3 patients, a larger
sample size is needed to reliably explore the relationship between mFI score and the
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outcomes of interest. Second, there are discrepancies between the all-procedure PUF
and procedure-specific PUF. For instance, diagnosis might be listed as “No malignancy”
in one but as “Neoplasm of the cardia” in the other. It is unclear if these inconsistencies
are intentional and based on other criteria, or simply due to human error in data
collection. In our study, the pathology from the esophagectomy PUF was used, as this
set of data was specific and likely more accurate for the population of interest.
Furthermore, the mFI-5 has not been prospectively validated. By virtue of this being a
retrospective study, we could only establish association. As such, it is difficult to know
the overlap of comorbidities within the mFI-5 as predictors of postoperative risk and as
indicators of frailty, and the temporal relationships between risk factors and outcome.

In conclusion, the simplified mFI-5 is associated with morbidity but not mortality in
patients who have undergone esophagectomy for esophageal cancer. Specifically, it is
significantly associated with 30-day ICU-level complications, return to the operating
room, and anastomotic leak. This study highlights the possibility that mFI-5, as
compared to its mFI-11 predecessor, may not have enough nuance in the frailty
assessment specific to the esophagectomy population.
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Chapter 3 – Sarcopenia and Modified Frailty Index are Not Associated with
Adverse Outcomes After Esophagectomy for Esophageal Cancer – A
Retrospective Cohort Study
3.1 Introduction
Esophageal cancer is a highly morbid disease with a 5-year overall survival of under
20%7. Weight loss, poor nutritional status, and depletion of lean muscle mass are
common in esophageal cancer patients49, where the mainstay of treatment is surgical
resection. An esophagectomy is a complex and physiologically demanding procedure
with high rates of surgery-related morbidity21–23.

Preoperative physiologic decline and cancer-related cachexia have been implicated in
poor perioperative outcomes for cancer patients but remain difficult to measure. Clinical
indicators of frailty (i.e., frailty indices), as well as radiographic measures (i.e., skeletal
muscle mass calculations), have previously been used to evaluate the link between
physiological reserve and adverse outcome with varying degrees of success.

Sarcopenia, defined as a state of low skeletal muscle mass and function, has been
associated with an increased risk of postoperative complications in esophageal cancer
patients after esophagectomy110. In a recent meta-analysis, sarcopenia was shown to
be a predictor of poor overall survival and disease-free survival in this patient
population130. Similarly, clinical scores aimed at identifying patients with low physiologic
reserve – such the Modified Frailty Index (mFI) from the American College of Surgeons
National Surgical Quality Improvement Program (ACS NSQIP) – have been promoted
as a simple, clinically-feasible measure of frailty in thoracic surgery patients86. The
original iteration of the mFI was demonstrated to be significantly associated with both
postoperative morbidity and mortality in esophagectomy patients148. Since then,
however, the mFI has been simplified to 5 factors (mFI-5), and the association between
this new score and adverse outcomes in this patient population is conflicting 149.
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Identifying disease and procedure-specific measures of perioperative risk is important
for improving both patient selection and the care of surgical patients. With more
accurate estimations of morbidity and mortality, interventions may be undertaken in
patients with poor prognostic indicators in the perioperative period. A better
understanding of surgical risk will also allow patients and surgeons to make more
informed decisions during the consent process.

Given the lack of clarity around whether radiographic or clinical measures of physiologic
reserve more accurately align with post-operative outcomes, in this study, we evaluated
both sarcopenia and the NSQIP mFI-5 and their association with adverse surgical
outcomes in the same cohort of patients undergoing esophagectomy for esophageal
cancer. We hypothesized that sarcopenia may be more strongly associated with
adverse outcomes than the mFI-5.

3.2 Methods
We retrospectively reviewed all consecutive patients who underwent an esophagectomy
at London Health Sciences Centre (LHSC) from January 2010 to December 2016.
LHSC is a tertiary care referral centre for thoracic surgery, with a catchment area of
over 1.5 million patients. Patients were identified from the prospectively collected local
thoracic surgery operative database. Patients were included if they were over 18 years
of age with esophageal dysplasia or cancer and a CT scan within 12 weeks prior to
surgery. Patients were excluded if they had benign disease, recurrent or unresectable
cancer discovered intraoperatively, non-esophageal malignancy, or concurrent
resection of other organ systems in addition to an esophagectomy. Patients were also
excluded if they did not have a documented height in the medical record, as this is
essential to determine sarcopenia status. The study was approved Western University
Research Ethics Board.

Data were obtained from the thoracic surgery operative database, as well as the
medical record for all included patients. Demographics data extracted included: age,
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sex, weight, height, date of surgery, functional status or ECOG score, ASA
classification, presence of diabetes, CHF, hypertension requiring medication, COPD,
and neoadjuvant treatment status.

3.2.1 Sarcopenia Measurement
The skeletal muscle mass was determined on preoperative CT scans within 12 weeks
prior to surgery. If a patient had undergone multiple CT scans, we used the last CT scan
prior to their esophagectomy. Aquarius NET server (TeraRecon, Inc., San Mateo, CA)
was used to measure the cross-sectional skeletal muscle mass at the level of the third
lumbar vertebra (L3). The skeletal muscle at the L3 level is known to correlate with both
the whole-body fat-free mass and appendicular skeletal muscle mass150. We selected a
single image on the level of L3 with both transverse processes and delineated
abdominal muscles. Psoas, quadratus lumborum, paraspinal, transverse abdominal,
external oblique, internal oblique, and rectus abdominis muscles were included. The
distinction between muscle and other tissues was based on Hounsﬁeld units (HU). A
threshold range of -29 to 150 HU was used to deﬁne skeletal muscle. The selected area
was manually adjusted, and the muscle area was calculated automatically by the
software (Figure 2). The cross-sectional total muscle area at the level of L3 (cm2) was
divided by the square of height (m2), which produced the skeletal muscle index (SMI).
This method is suggested as the preferred method of measuring the muscle mass of
cancer patients116. SMI limit for sarcopenia was < 52.4 cm2/m2 for men and < 38.5
cm2/m2 for women, based on a previous study by Prado et al.116.
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Figure 2. Abdominal computed tomography assessment of body composition for two
male patients with esophageal cancer using skeletal muscle area normalized by height.
Patient (A) does not have sarcopenia (skeletal muscle index 62.03 cm 2/m2) compared to
patient (B) who is sarcopenic (skeletal muscle index 38.58 cm2/m2).

3.2.2 Frailty Measurement
Frailty was assessed using the ACS NSQIP 5-factor modified frailty index, which
consists of 1) hypertension requiring medication, 2) diabetes, 3) COPD; 4) functional
status, and 5) CHF. This information was collected from preoperative assessment notes
similar to the definitions found in the ACS NSQIP PUF102.

Patients were classified as either independent or partially dependent based on
documented ECOG score, exercise tolerance, or assistance with activities of daily
living. Patients with an ECOG score of 1 or more, exercise tolerance noted to be
reduced, or noted to require additional supports with activities of daily living (ADL) were
classified as partially dependent. Where these components of functional status were not
mentioned, and the clinical notes suggested the patient was likely independent,
functional status was classified as such.
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The mFI-5 score was calculated for each patient by adding the number of variables
present, with 0–5 total points possible. We chose to not assign weights to each deficit to
keep the determination of the mFI-5 as simple as possible, which is in keeping with
other studies using the mFI81,98,103.

3.2.3 Outcomes of interest
The primary outcome was unplanned ICU admission within 30-days. This was chosen
as a composite marker for severe surgical complications according to the Clavien-Dindo
classification, where grade IV is defined as a life-threatening complication requiring ICU
management132. Compared to our NSQIP study, ICU admission since this was more
reliably documented and clinically relevant outcome, whereas details of specific
complications were not always available.

Secondary outcomes included 30-day readmission due to surgical complications, 90day all-cause mortality, hospital stay over 30 days, return to the operating room, and
anastomotic leak of any grade. Return to the operating room status is recorded to
include all major surgical procedures that required the patient to be taken to the
operating room for intervention of any kind.

3.2.4 Statistical Analysis
Data were described as means with standard deviations for normally distributed
continuous variables, medians with interquartile ranges for non-normally distributed
continuous variables, and frequencies with associated percentages for categorical
variables. Shapiro-Wilk normality test was used to determine normality of continuous
variables: age, BMI, total length of stay, and operation duration. A convenience sample
size of all patients who underwent an esophagectomy between 2010-2016 were
included, in line with the record keeping of the esophagectomy database.
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Relationships between categorical variables were assessed using Pearson chi-squared
test or Fischer’s exact test, where appropriate. For continuous variables, one-way
ANOVA or Kruskal-Wallis rank sum test was used to compare between groups.
Univariate logistic regression was used to determine the odds ratio in unadjusted
comparisons between sarcopenia status and outcomes, as well as mFI-5 scores and
outcomes.

Multivariate logistic regression models were completed to provide an adjusted estimate
of the independent contribution of sarcopenia and mFI-5 score on the outcome of
unplanned ICU admission. Variables were chosen for the models based on 1)
demonstrated statistical significance with sarcopenia and/or mFI-5 score on univariate
analysis, or 2) a known to be clinically associated with adverse surgical outcomes
based on existing literature. Due to the small sample size of the final analysis, only
three additional covariates were included in the multivariate logistic regression: age,
ASA classification, and neoadjuvant therapy status. ASA classification has been shown
to be reliable predictor of poor postoperative outcomes151,134,152 and was used in this
study as an overall marker of comorbidity. Since no patients had an ASA of 1 and only
five had an ASA of 2, ASA 1, 2, and 3 were combined into a new ASA variable to
compare ASA 1-3 versus ASA 4. Neoadjuvant therapy was coded as having been
received if the patient received chemotherapy, radiation therapy, or both to treat their
esophageal cancer prior to operative intervention.

Results from regression analyses are presented as adjusted odds ratio (OR) along with
95% CI and P values. In all comparisons, a p-value of less than 0.05 was considered
significant. All statistical analysis was carried out using SPSS software, version 27 (IBM,
Armonk, New York, USA).
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3.3 Results
3.3.1 Patient Demographics
A total of 331 patients underwent an esophagectomy at LHSC from 2010 to 2016. There
were 126 patients who were excluded, primarily due to the lack of height recorded (n =
12) or availability of preoperative CT scans within 12 weeks (n = 81). Other reasons for
exclusion included extensive concomitant major resection of other organ systems,
inability to complete resection, and non-esophageal malignancy on pathology (n = 33).
A total of 205 patients who underwent esophagectomy for esophageal cancer were
included in the final analysis.

Patient demographics are summarized in Table 9 and 10. The median age was 66
years (IQR 58-72) with the median BMI being 26.5 (IQR 23-30.9). Of the analysis
population, 118 patients (57.6%) were classified as sarcopenic and 87 patients (42.4%)
non-sarcopenic. Calculated mFI-5 scores for all patients in the study sample ranged
from 0 to 3; no patients who underwent an esophagectomy had a mFI-5 score of 4 or 5.
The number of patients with each mFI score were as follows: 91 patients had mFI 0
(44.4%), 72 patients had mFI 1 (35.1%), 34 patients had mFI 2 (16.9%), and 8 patients
had mFI 3 (3.9%). Within the mFI, hypertension requiring medication was the most
common comorbidity (80 of 205, 39%), followed by diabetes (43 of 205, 21%) (Table
11). Patients with sarcopenia and patients with higher mFI-5 scores were significantly
older (P <0.001 and P=0.017, respectively). Conversely, lower BMI was found in
patients with sarcopenia (P <0.001) while higher BMI was seen in patients with higher
mFI-5 score (P = 0.081).
Median operation duration was 272 minutes (IQR 223 – 334) and was not significantly
different between groups. Most study patients were male (170 of 205, 82.9%). Sex was
associated with sarcopenia status (p = 0.002), with a higher proportion of men in the
sarcopenia group (106 of 118, 89.8%). Sex was not associated with mFI score (p=0.41).
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The most common pathology was adenocarcinoma (168 of 205, 82%), which made up a
larger proportion in the non-sarcopenic group (78 of 87, 89.7%) compared to the
sarcopenic group (90 of 118, 76.3%). Conversely, squamous cell carcinoma pathology
was three times larger in the sarcopenic group (22 of 118, 18.6%) compared to the nonsarcopenic group (6 of 87, 6.9%).

Table 9 – Local esophagectomy patient demographics by sarcopenia status
Sarcopenia
Characteristic
Age (years)
Median [IQR]
BMI (kg/m2)
Median [IQR]
Missing data (%)
Operation duration
(mins)
Median [IQR]
Sex
Male
Female

Overall
N = 205

No
N = 87

Yes
N = 118

p-value1

66 [58-72]

64 [54- 69.5]

67 [61- 75.8]

<0.0012

26.5 [23-30.9]
36 (17.6%)

29.8 [26.7- 33.5]
18 (20.7%)

24.4 [21.8- 27.8]
18 (15.3%)

<0.0012

272 [223-334]

272 [218.5-331]

276.5 [230.5336.2]

0.922
0.002

170 (82.9%)
35 (17.1%)

64 (73.6%)
23 (26.4%)

Pathology
Adenocarcinoma
168 (82%)
78 (89.7%)
SCC
28 (13.7%)
6 (6.9%)
Mixed
6 (2.9%)
1 (1.1%)
Dysplasia
3 (1.5%)
2 (2.3%)
ASA Classification
1
0 (0%)
0 (0%)
2
5 (2.4%)
4 (4.6%)
3
138 (67.3%)
59 (67.8%)
4
62 (30.2%)
24 (27.6%)
1-3
143 (69.7%)
63 (72.4%)
4
62 (30.2%)
24 (27.6%)
Neoadjuvant
85 (41.5%)
29 (33.3%)
Therapy
1Pearson's Chi-squared test; Fisher's exact test
2Kruskal-Wallis rank sum test

106 (89.8%)
12 (10.2%)
90 (76.3%)
22 (18.6%)
5 (4.2%)
1 (0.8%)

0.014
0.015

0.20
0 (0%)
1 (0.8%)
79 (66.9%)
38 (32.2%)
80 (67.8%)
38 (32.2%)
56 (47.5%)

0.48
0.042
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Overall, neoadjuvant therapy was used in 41.5% (85 of 205) of patients. More patients
with sarcopenia had undergone neoadjuvant therapy (56 of 118, 47.5%) compared to
non-sarcopenic patients (29 of 87, 33.3%); however, the proportion of patients who
underwent neoadjuvant decreased with higher mFI-5 score.

Table 10 – Local esophagectomy patient demographics by mFI-5 score

Characteristic

mFI-5 Score
1
2
N = 72
N = 34

Overall
N = 205

0
N = 91

3
N=8

p-value1

66
[58-72]

62.0
[54-70]

67.0
[60.5-73]

67.5
[62.5-71]

70
[66.2-77.2]

0.0172

26.5
[23-30.9]
36 (17.6%)

25.8
[22.4-28.8]
18 (19.8%)

26.5
[23.0-31.2]
11(15.3%)

28.4
[26.2-32.1]
6(17.6%)

29.2
[24.9-31.9]
1(12.5%)

0.0812

272
[223-334]

279
[227-337]

264
[220-337]

315
[234.8-357.2]

223.5
[209.8-274]

0.312

Age (years)
Median [IQR]
BMI (kg/m2)
Median [IQR]
Missing data (%)
Operation duration
(mins)
Median [IQR]
Sex

0.41
170
(82.9%)
35 (17.1%)

Male
Female

72 (79.1%)

63 (87.5%)

29 (85.3%)

6 (75%)

19 (20.9%)

9 (12.5%)

5 (14.7%)

2 (25%)

Pathology
Adenocarcinoma

168 (82%)

70 (76.9%)

61 (84.7%)

30 (88.2%)

7 (87.5%)

0.44

SCC

28 (13.7%)

17 (18.7%)

8 (11.1%)

2 (5.9%)

1 (12.5%)

0.24

Mixed

6 (2.9%)

2 (2.2%)

2 (2.8%)

2 (5.9%)

0 (0%)

Dysplasia

3 (1.5%)

2 (2.2%)

1 (1.4%)

0 (0%)

0 (0%)

ASA Classification

0.19

1

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

2

5 (2.4%)
138
(67.3%)
62 (30.2%)
143
(69.7%)
62 (30.2%)

4 (4.4%)

1 (1.4%)

0 (0%)

0 (0%)

67 (73.6%)

47 (65.3%)

20 (58.8%)

4 (50%)

20 (22%)

24 (33.3%)

14 (41.2%)

4 (50%)

71 (78%)

48 (66.7%)

20 (58.8%)

4 (50%)

20 (22%)

24 (33.3%)

14 (41.2%)

4 (50%)

44 (48.4%)

29 (40.3%)

10 (29.4%)

2 (25%)

3
4
1-3
4
Neoadjuvant
Therapy
1Pearson's

85 (41.5%)

Chi-squared test; Fisher's exact test
rank sum test

2Kruskal-Wallis

0.083

0.20
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Table 11 – Local esophagectomy patient comorbidities by mFI-5 score
mFI-5 Score
Comorbidity

Overall
N = 205

0
N = 91

1
N = 72

2
N = 34

3
N=8

Hypertension on
medication*

80 (39%)

0 (0.0%)

42 (58.3%)

30 (88.2%)

8 (100.0%)

Diabetes*

43 (21%)

0 (0.0%)

12 (16.7%)

23 (67.6%)

8 (100.0%)

Chronic obstructive
pulmonary disease*

27 (13.2%)

0 (0.0%)

14 (19.4%)

8 (23.5%)

5 (62.5%)

Functionally dependent*

6 (2.9%)

0 (0.0%)

1 (1.4%)

3 (8.8%)

2 (25.0%)

Congestive heart failure*

3 (1.5%)

0 (0.0%)

1 (1.4%)

2 (5.9%)

0 (0.0%)

Smoking

56 (27.3%)

28 (30.8%)

15 (20.8%)

11 (32.4%)

2 (25.0%)

3.3.2 Outcomes
Outcomes according to sarcopenia status and mFI-5 score are shown in Tables 12 and
13. Overall, unplanned ICU admission occurred in 19% (39 of 205) of patients. Mortality
within 30 days, which were all in-hospital, occurred in 3.4% (7 of 205). Mortality within
90 days was 5.4% (11 of 205). Readmission within 30 days occurred in 17.1% (35 of
205). The median length of hospital stay was 11 days (IQR 9-16), with 6.3% (13 of 205)
of patients staying over 30 days. Return to the operating room occurred in 22.4% (46 of
205), while 25.4% (52 of 205) of patients experienced an anastomotic leak and 8.3%
(17 of 205) experienced a chylothorax.

Patients defined as sarcopenic were more likely to require an ICU admission, 30-day
mortality and readmission, 90-day mortality, return to the operating room, anastomotic
leak, and chylothorax were all higher in the sarcopenic group (Table 12).
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Variables that showed an increasing trend with higher mFI-5 score include: 30-day
mortality and readmission, 90-day mortality, median length of stay in hospital, and
hospital stay over 30 days. The rate of ICU admission, return to the operating room, and
anastomotic leak increased from mFI 0 to 1 and from mFI 1 to 2, but decreased for mFI
3 (Table 13).

Table 12 – Local esophagectomy patient outcomes by sarcopenia status
Sarcopenia
Outcome

Overall
N = 205

No
N = 87

Yes
N = 118

p-value1

ICU admission

39 (19%)

16 (18.4%)

23 (19.5%)

0.84

30-day mortality

7 (3.4%)

2 (2.3%)

5 (4.2%)

0.70

90-day mortality

11 (5.4%)

2 (2.3%)

9 (7.6%)

0.12

30-day readmission
Length of hospital stay
(days)

35 (17.1%)

16 (18.4%)

19 (16.1%)

0.67

11 [9-16]

10 [9- 16]

11 [9- 15]

0.402

Length of stay >30 days

13 (6.3%)

6 (6.9%)

7 (5.9%)

0.78

Return to OR

46 (22.4%)

16 (18.4%)

30 (25.4%)

0.23

Anastomotic leak

52 (25.4%)

21 (24.1%)

31 (26.3%)

0.73

5 (5.7%)

12 (10.2%)

0.26

Median [IQR]

17 (8.3%)
Chylothorax
1 Pearson's Chi-squared test; Fisher's exact test
2 Wilcoxon rank sum test
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Table 13 – Local esophagectomy patient outcomes according to mFI-5 score
mFI-5 Score
Outcome

Overall
N = 205

0
N = 91

1
N = 72

2
N = 34

3
N=8

p-value1

ICU admission

39 (19%)

13 (14.3%)

14 (19.4%)

10 (29.4%)

2 (25%)

0.22

7 (3.4%)

2 (2.2%)

2 (2.8%)

2 (5.9%)

1 (12.5%)

0.21

11 (5.4%)

4 (4.4%)

2 (2.8%)

4 (11.8%)

1 (12.5%)

0.14

35
(17.1%)

12 (13.2%)

14 (19.4%)

7 (20.6%)

2 (25%)

0.50

Median [IQR]

11 [9-16]

10 [9- 13]

11 [9- 16]

12 [10- 18]

16 [11- 23]

0.0122

Length of stay
>30 days

13 (6.3%)

3 (3.3%)

4 (5.6%)

4 (11.8%)

2 (25%)

0.045

15 (16.5%)

20 (27.8%)

10 (29.4%)

1 (12.5%)

0.21

19 (20.9%)

18 (25.0%)

13 (38.2%)

2 (25%)

0.26

11 (12.1%)

4 (5.6%)

2 (5.9%)

0 (0%)

0.45

30-day
mortality
90-day
mortality
30-day
readmission
Length of
hospital stay
(days)

Anastomotic
leak

46
(22.4%)
52
(25.4%)

Chylothorax

17 (8.3%)

Return to OR

1 Pearson's

Chi-squared test; Fisher's exact test
rank sum test

2 Kruskal-Wallis

We performed univariate and multivariate regression analyses for sarcopenia and frailty
separately, which did not demonstrate significant associations with postoperative ICU
admission (Table 13). Notably on univariate analysis, ASA 4 status doubles the odds of
ICU admission (OR 2.08, p=0.046; 95% CI 1.01-4.27) while neoadjuvant therapy almost
halves the odds of ICU admission (OR 0.49, p=0.065; 95% CI 0.23-1.05). After
adjusting for the effects of age, comorbidity (ASA class) and the receipt of neoadjuvant
therapy, neither sarcopenia status (OR 1.00, 95% CI 0.47 – 2.15), nor mFI Score (OR
1.18, 95% CI 0.49-2.79 for mFI 1; OR 1.87, 95% CI 0.70 – 4.99 for mFI 2; OR 1.29,
95% CI 0.22 – 7.61 for mFI 3) were significant associated with unplanned ICU
admission (Table 14).
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Table 14 – Adjusted Odds Ratio of ICU admission accounting for sarcopenia vs
mFI-5 and covariates of multivariate logistic regression (P; 95% CI)
Variable

Logistic regression 1

Logistic regression 2

Sarcopenia

1.00 (0.996; 0.47-2.15)

N/A

mFI 1 (vs. 0)

N/A

1.18 (0.706; 0.49-2.79)

mFI 2 (vs. 0)

N/A

1.87 (0.212; 0.70-4.99)

mFI 3 (vs. 0)

N/A

1.29 (0.773; 0.22-7.61)

Age

1.02 (0.246; 0.98-1.06)

1.02 (0.301; 0.98-1.06)

ASA 4 (vs. 2 and 3)

1.91 (0.083; 0.92-3.97)

1.79 (0.124; 0.85-3.79)

Neoadjuvant therapy

0.56 (0.152; 0.25-1.24)

0.59 (0.185; 0.27-1.29)

3.4 Discussion
The aim of this study was to assess two measures of physiologic reserve – sarcopenia
and frailty – and their association with surgical morbidity and mortality after
esophagectomy for esophageal cancer. This is the first study to describe both metrics in
the same cohort of esophagectomy patients.

The prognostic value of these measurements has gained interest in recent years due to
the possibility of identifying modifiable risk factors implicated in postoperative
complications and survival. Our results did not demonstrate a significant association
between either sarcopenia or frailty – as measure by mFI-5 – and major postoperative
complications. In our study, the prevalence of sarcopenia and frailty were both high,
with more than half of our study population being sarcopenic (57.6%) or having some
score of frailty (55.6% scored mFI 1-3). Previous studies that use the same sarcopenia
measurement and cut-off values116 have reported rates of sarcopenia ranging from
15.9%153 to 80%154, while the prevalence of frailty in larger database cohorts reported
similar levels, with over half the study population having some score of frailty (55.6%
scored mFI 1-3)149. The prevalence of both conditions in the population of patients
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presenting for esophagectomy makes these measures of decreased physiologic reserve
logical targets for potentially modifiable factors in the pathway to poor postoperative
outcomes.

The existing literature examining the impact of sarcopenia on esophagectomy outcomes
for cancer patients has demonstrated consistency in the association with respiratory
complications121,122,127,129,154,155, but there is little consensus on anastomotic leak,
chylothorax, and complications above Clavien-Dindo grade III127. The main difficulties in
comparing results of these studies lies in the significant variability in baseline
characteristics (e.g. race, tumour stage, histology, type of operation, neoadjuvant
therapy) and sarcopenia cut-off values154. Since there are no standardize
measurements for sarcopenia cut-offs, we chose to use the values put forth by Prado et
al.116 for our study, as these appear to the most widely used and well studied set of
parameters in existing literature.

Similar issues of heterogeneity exist within the frailty literature, even when the same
frailty assessment tool is used. Our previous study using the NSQIP database found
higher mFI-5 scores were associated with Clavien-Dindo grade IV complications149;
however, this finding was not replicated in our current single-center study.
Reproducibility is difficult in different study populations because of the disparities in
record keeping, data availability, and how outcomes are defined. For example, our local
patient cohort had similar age, BMI, and sex distributions compared to the NSQIP
patients; however, we had significantly more ASA class 4 patients (30.2%) compared to
NSQIP (6.9%), as well as fewer patients who underwent neoadjuvant therapy (41.5%,
vs. NSQIP neoadjuvant chemotherapy 69.7% and radiation 59.4%). In the NSQIP
study, Clavien-Dindo grade IV was a composite outcome of life-threatening
complications that were presumed to be managed in an ICU – it is possible a
myocardial infarction or stroke may not have needed to be monitored in the intensive
care setting. In the current study, disposition to the ICU was a recorded outcome
regardless of the complication, which provides a more useful and clinically relevant level
of granularity.
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A key factor to consider in using sarcopenia or frailty is the dynamic nature of
physiologic reserve. The detrimental effects of neoadjuvant therapy on muscle mass,
strength, and function are well documented in literature 115,154,156–158. This idea that
sarcopenia measured at a single point in time does not necessarily predict a poor
postoperative outcome in esophageal cancer patients was demonstrated in a study by
Järvinen et al. which found no statistical difference in 2-year overall survival or
recurrence-free survival between the preoperative sarcopenic and non-sarcopenic
groups until patients were analyzed based on the amount of change in sarcopenia 154.
This suggests that there is a much more complex interaction that occurs across time
between the benefits of neoadjuvant therapy and the resulting harm of sarcopenia in
determining adverse surgical outcome. Though the limitations of our imaging
capabilities – specifically the inability to calculate sarcopenia score on images obtained
outside our institution – prevented us from capturing change in sarcopenia over time, it
is possible that this measure may have been more sensitive in demonstrating a
relationship between sarcopenia status and unplanned ICU admission.

For mortality specifically, our results were consistent with other studies that looked at
30-day and in-hospital mortality – sarcopenia did not significantly increase the risk of
death in the immediate postoperative period. However, we did note that 90-day mortality
(OR 3.51, p = 0.11; 95% CI 0.74-16.67) was much higher than 30-day mortality (OR
1.88; p= 0.457, 95% CI 0.36-9.93). In studies with longer follow-up periods ranging from
1 to 8 years, sarcopenia significantly reduced both overall survival and disease-free
survival in esophageal cancer patients who had undergone surgical
resection122,155,158,159. One possible explanation is that the effects of sarcopenia are
cumulative; the loss of muscle mass and function might not be a better marker of risk for
short term mortality but a marker of long-term vulnerability to disease- and treatmentrelated stressors that decrease survival rather than a marker of long-term survival.

Although there are currently no standardized metrics of determining physiologic
suitability for an esophagectomy, our results support the hypothesis that surgeons are
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apt at making decisions about who should proceed to esophagectomy at all. The lack
of patients with a frailty score above mFI 3 suggests that patients with higher levels of
frailty are not even presenting for surgery, which impacts our understanding of the role
of frailty in postoperative outcomes. Furthermore, it is interesting to note that in our
study the proportion of patients who underwent neoadjuvant therapy was higher in the
sarcopenia group (47.5% vs 33.3% non-sarcopenic group) but showed a decreasing
trend with higher frailty scores (48% mFI 0, 40.3% mFI 1, 29.4% mFI 2, 25% mFI 3).
This disparity perhaps suggests that sarcopenia and mFI-5 capture different traits of
physiologic reserve that were factored into the treatment decision-making process. Our
previous study with 2,567 patients from the international NSQIP database did not
observe the same trend with frailty149, possibly indicating a difference in institutional
treatment or referral patterns that are not accounted for in this study.

The strengths of this study include being the first to use frailty and sarcopenia
measurements in the same esophagectomy cohort where the primary endpoint is
measured by a clinically relevant outcome (i.e., admission to ICU). Our study has a few
notable limitations. This was a single-center study with a small sample size and an even
smaller cohort of patients who had the outcomes of interest. As such, this did not allow
us to perform a robust multivariate regression analysis, account for stage of disease or
the type of surgery performed. Our patients also did not have the full range of frailty
scores, as no one scored higher than 3/5 on the mFI-5. This phenomenon was also
observed in our NSQIP study149, reaffirming that the mFI-5 perhaps does not have the
granularity to capture the nuances of frailty assessment specific to patients who
undergo an esophagectomy for cancer, or that surgeons are selecting patients with
lower frailty scores as appropriate for esophagectomy.

In conclusion, neither sarcopenia nor frailty as measured by mFI-5 demonstrated an
association with 30-day morbidity or mortality for esophageal cancer patients in our
single-center study. Overall, sarcopenia and frailty can be markers of increased
physiologic vulnerability as they reflect the cumulative effects of aging, disease
progression, malnutrition, and weight loss. There appears to be both overlap and
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disparities in these measures of physiologic reserve, but they do not always correspond
with statistically and clinically significant outcomes. The interaction between sarcopenia,
frailty, and other preoperative factors that affect measures of physiologic reserve may
be more nuanced and should be further explored in a prospective manner with a larger
patient population.
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Chapter 4 – Discussion and Conclusion
4.1 Discussion
The purpose of this thesis was to investigate the association between frailty,
sarcopenia, and adverse surgical outcomes in patients who have had an
esophagectomy for esophageal cancer. This was approached by first examining mFI-5
using NSQIP, and then local data for mFI-5 and sarcopenia. By the natural course of
this disease, it is not surprising that patients with esophageal cancer have a high
incidence of unintended weight loss (>70%) and sarcopenia (26–75%) at diagnosis115.
While modern treatment modalities – surgery, chemotherapy, and radiation therapy –
improve survival, they take a significant physiological toll, which often worsen
malnutrition, physical deconditioning, and muscle wasting in the preoperative
period115,160. As we march forward in the era of personalized medicine, we are
beginning to understand that pre-treatment physiologic reserve, as measured by metrics
such as frailty and sarcopenia, are truly critical determinants of surgical outcomes161. An
improved understanding of the association between states of decreased physiologic
reserve and perioperative morbidity is the first key step in designing interventions to
minimize risk and improve patient outcomes.

4.1.1 Literature Review Summary
In Chapter 1, we reviewed the current literature on frailty and sarcopenia, which
demonstrated the importance of understanding the impact of physiology reserve on
adverse surgical outcomes. In the context of esophageal cancer, however, our review
identified a substantial gap in knowledge. Over the last few decades, the concept of
frailty has become increasingly recognized as an important determinant of health
outcomes. Defining frailty, however, is challenging, with over 50 different tools in
existence to capture this metric. These tools range from dichotomous metrics to
continuous scales that account for physical, social, and psychosocial domains. Few of
these frailty scoring systems have been validated in surgical oncology, and certainly
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frailty in the context of esophageal cancer surgery has not been well studied. The state
of research is such that we apply existing generalized frailty assessments to unique
pathologies, not knowing if the metrics are nuanced enough to capture disease- or
surgery-specific qualities. There remains substantial room in the literature to explore the
use of existing tools in the context of esophagectomy to esophageal cancer.

4.1.2 NSQIP mFI-5 Summary
In Chapter 2, we performed a retrospective cohort study to define the utility of a single
frailty measure – the 5-factor mFI – in patients undergoing esophagectomy for
esophageal cancer and dysplasia. The National Surgical Quality Improvement Program
database for esophagectomy patients who underwent surgery for cancer or pre-cancer
was used to investigate the association between the 5-factor mFI and the occurrence of
post-operative complications and death within 30 days of surgery. While previous
NSQIP studies using the extended 11-factor mFI in patients with esophageal cancer98,
as well as those using the 5-factor mFI in a general population of thoracic surgery
patients, demonstrated associations with mortality and morbidity
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our study

demonstrated some conflicting results with respect to the association between the mFI5 and outcomes in patients undergoing esophagectomy.

Using the mFI-5, we showed that higher frailty scores were indeed associated with a
higher incidence of severe complications requiring ICU level care. Our results confirmed
our hypothesis that patients with higher scores in frailty have higher rates of severe
complications.

In Chapter 2, the lack of patients with frailty scores higher than mFI 3 likely means
patients who had four or five of the mFI comorbidities were not offered surgery. Whether
it is because these patients never make it to surgery, or because surgeons are simply
not offering surgery, there is likely a combination of selection bias and clinical
judgement that is unaccounted for in way frailty is measured by the mFI-5. We must
consider the possibility that the mFI-5, unlike its 11-factor predecessor, may not be
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nuanced enough to explore vulnerabilities specific to esophageal cancer and
esophagectomies, thereby underestimating the true markers of frailty in these patients.
This, perhaps more than any statistical results, serves as the best indictment against
relying solely on mFI-5 as a preoperative decision-making tool in this patient population.

4.1.3 Sarcopenia and mFI-5 in Local Cohort Summary
The milestones of Chapter 3 were several folds. First, we aimed to replicate the findings
from Chapter 2 by applying mFI-5 to our local patient population. The primary outcome
in this study was postoperative ICU admission rather than Clavien-Dindo grade IV
complications. ICU admission status was chosen because in Chapter 2 we had to
assume grade IV complications would be managed in an intensive care setting, as
neither this grading nor ICU status was an outcome assigned by the NSQIP database.
ICU admission is not only a more pragmatic outcome in understanding the treatment
process of this complex disease, but it also serves as a concrete and important
endpoint for decision-making by the patient and their care team. ICU admission is also
an immensely useful surrogate for resource intensity – a factor that must be ever salient
in a public health care system and particularly relevant during the current pandemic
where ICU beds are scarce and intensive care resources have been stretched thinner
than ever before.

Second, given that physiologic reserve is multifactorial and multidimensional, we wished
to measure frailty and sarcopenia in the first study to describe these two measures of
physiologic reserve in the same cohort of esophagectomy patients. Although neither
proved to be associated with morbidity or mortality in a significant way, this study did
highlight important challenges in the contemporary evaluation of both frailty and
sarcopenia.
The concept of sarcopenia – decreased muscle mass and function – is intuitively simple
but difficult to standardize. Even when the same objective functions of sex, height, and
skeletal muscle area are used, there are crucial components many studies fail to take
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into account. One important consideration, as mentioned in Chapter 3, is the dynamic
nature of physiologic reserve. Our study captured sarcopenia measurements within a
12-week interval between preoperative imaging and surgery since no standardized time
cut offs exist. During this period, we did not account for how sarcopenia status may
have changed with neoadjuvant therapy, enteral feeding, or disease-related decline. It is
therefore difficult to understand how certain temporally important variables impact
outcome. This temporal relationship warrants further clarification, especially given that
previously studies have shown the amount of change in sarcopenia was associated with
2-year overall survival and recurrence-free survival154. Future studies should require not
only standardization but also adjustments for nutrition, physical exercise, neoadjuvant
therapy, and any factors that are specific to esophageal cancer or institutional
differences (e.g., esophageal stenting, feeding tube insertion, pre-habilitation regimens)
that could change sarcopenia leading up to surgery.

While the relationship between mFI-5 and adverse outcomes was not statistically
significant in Chapter 3, we did note a trend towards increased ICU admissions in
patients with mFI scores of 1 and 2. Furthermore, the results in both Chapter 2 and 3
showed a general trend towards increased mortality in patients with higher mFI-5
scores. While we cannot draw any definitive conclusions, the wide confidence intervals
of higher frailty scores lead us to believe that a significant limitation to evaluating mFI-5
in our local cohort is the small sample size. While the NSQIP sample size was large, the
number of patients with high frailty scores is too small. A larger, multicentered study,
ideally conducted in a prospective manner, is the next step to verifying the utility of the
mFI-5 in esophagectomy patients. The small sample size of the desired cohort also
points to a secondary limitation and highlights the importance of what the mFI-5 does
and does not capture. Similar to the NSQIP database, no patients in our local cohort
who had undergone an esophagectomy for esophageal cancer had an mFI-5 score
above three. As is the nature of retrospective studies, our sample population only
captured patients who completed the procedure. The five factors in the mFI-5 are such
general metrics of health that presumably those who check more than three boxes are
so moribund in unaccounted ways that they may not be offered an esophagectomy or
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simply do not make it to surgery. As such, the challenge in identifying frail esophageal
cancer patients who are more at risk when undergoing an esophagectomy, or indeed
any surgical procedure, is tailoring assessment tools specific to the surgery or disease.
In this way, perhaps mFI-5 not only requires further investigation in a larger, more
adequately powered study, but also the addition of other metrics of physiologic reserve.

With the future of medicine headed increasingly towards individualized therapies,
individualization must begin much earlier in the therapeutic process such that modifiable
risk factors are identified and mitigated before reaching the treatment step. This
requires focusing on disease specific outcomes, which mandates a tailored index that
addresses the risks specific to each patient population. While mFI-5 and sarcopenia are
useful tools to assess poor physiologic reserve at a glance, their components do not
address the risks unique to an esophagectomy. For esophageal cancer patients
undergoing an esophagectomy, assessments should occur at multiple points in the
timeline of their treatment, taking into account significant events including but not limited
to: neoadjuvant treatment, feeding tube insertion, changes to nutritional status, status of
social supports, changes to lean muscle mass, and deterioration in mobility or function.
A new index tailored for esophagectomy patients should address most, if not all, of
these multidimensional aspects; finding the best metrics to quantify these factors will be
the next step in the development of an esophagectomy-specific risk assessment tool.

4.3 Conclusions
Esophageal carcinoma is a complex disease, and the perioperative risk management of
esophageal resection is more complex still. Patients are at high risk of physical
deconditioning, which can lower tolerance to physical stressors and in turn increase the
risk for surgical morbidity. Our current understanding of how physiologic reserve
impacts esophagectomy outcomes is limited and largely siloed to discrete, static metrics
with few considerations for the disease or treatment in question.
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By applying the NSQIP 5-factor Modified Frailty Index to this patient population, we
identified an association between mFI-5 score and severe 30-day postoperative
complications, but not mortality. Further prospective studies with larger sample sizes
are warranted to assess specific outcomes of interest. Until then, it is our opinion that
this frailty scale has a limited role in aiding preoperative decision-making since it only
accounts for non-modifiable risk factors and lacks the nuance specific to
esophagectomy patients.

With regards to sarcopenia, despite literature that connects preoperative sarcopenia to
adverse post-esophagectomy outcomes, our study did not find any differences in
sarcopenia status and 30-day morbidity or mortality. The lack of temporal
standardization and consideration for esophageal cancer-specific factors, such as
perioperative feeding tube insertion and neoadjuvant therapy, could account for the
disparity in our results compared to the existing literature. These considerations could
potentially represent substantial changes in sarcopenia measurement. We should
therefore avoid dismissing the utility of sarcopenia in this patient population until further
studies accounting for these changes can be conducted.

Physiology reserve is dynamic, and much like the multidisciplinary approach to caring
for patients with esophageal cancer, the approach to measuring frailty and sarcopenia
should be equally multidimensional. Further research is still needed to identify the best
metric to quantify physiologic reserve so that we may better individualized management
strategies and optimize care for patients undergoing esophagectomies for esophageal
cancer.
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